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DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY?:  
REGULATORY REFORM OF HUMAN CLINICAL RESEARCH TO 
RAISE RESPONSIVENESS TO THE REALITY OF HUMAN 
VARIABILITY 
MICHAEL J. MALINOWSKI* AND GRANT G. GAUTREAUX** 
ABSTRACT 
Scathing critiques of the Food and Drug Administration’s (“FDA”) 
performance by the Government Accountability Office and Institutes of 
Medicine, a plummet in innovative new drug approvals in spite of significant 
annual investment increases in biopharmaceutical research and development 
(“R&D”), and market controversies such as the painkiller Vioxx and the 
diabetes drug Avandia (both associated with significantly escalated risks of 
heart attacks and strokes) have raised doubts about the sufficiency of FDA 
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Global “Gold Standard” for Drug Research and Development, 45 CORNELL INT’L LAW J. 
(forthcoming 2012). 
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regulation.  This Article questions how prescription medicines reach the 
market and proposes law-policy reforms to enhance the FDA’s science 
standard for human clinical trials and new drug approvals.  The core message 
is that relying too heavily on clinical research data generated through the 
global “gold standard” of group experimental design—reliance on statistical 
analysis to compile and compare group averages—risks predicting little about 
the actual impact of prescription medicines on individuals, including members 
of the groups under study.  This Article introduces a law-policy methodology 
based upon commercial incentives and intervention by Congress and the FDA 
to raise the science standard for human clinical research, and to make drug 
development more closely parallel the reality of drug delivery in the practice of 
medicine.  The objectives of this proposal are to promote several pressing 
needs: maximize drug performance and minimize adverse events; end the 
pattern of putting new prescription medications on the market with too much 
dependence on the medical profession to introduce meaningful clinical 
understanding of drugs through patient use over time; improve 
biopharmaceutical R&D decision making; align the regulatory standard with 
the infusion of added precision associated with contemporary genetics-based 
R&D; and realize more sound scientific information directly through the 
regulatory process to support the integrity of science in an age of academia-
industry integration, aggressive commercialization, secrecy in science, and 
constantly, rapidly evolving technology. 
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“2007 was the single worst year for new drug approvals in a quarter century 
and 2008 proved to be only slightly better.”1 
 
“[T]he drug industry’s research productivity has been declining for 15 years, 
‘and it certainly doesn’t show any signs of turning upward’. . . .”2 
 
“At present, our best advice for anyone concerned with the pharmaceutical 
treatment of behavior disorders in people with developmental disabilities is 
simple: Be skeptical and collect data.”3 
INTRODUCTION 
“Emma will never speak” was the conclusion of health care professionals 
when she was assessed for significant learning disabilities at the age of three.4  
Confirming what her parents had suspected and feared for much of her life, 
these health care professionals diagnosed Emma with an autism spectrum 
disorder.5  Autism or not, Emma’s parents did not accept the notion that their 
 
 1. G. Steven Burrill, Polishing the Crystal Ball: G. Steven Burrill Predicts What’s Ahead 
for Biotech in 2009, BURRILL REPORT (Jan. 2, 2009), http://www.burrillreport.com/article-
980.html.  The FDA approved eighteen innovative new drugs in 2007, twenty-four in 2008, and 
twenty-six in 2009.  Ed Silverman, How Many New Drugs Did FDA Approve Last Year?, 
PHARMALOT (Feb. 18, 2011, 9:35 AM), http://www.pharmalot.com/2011/02/how-many-new-
drugs-did-fda-approve-last-year; New Drug Approvals on Pace to Exceed 2008 Total, RES. 
RECAP (June 9, 2009), http://www.alacrastore.com/blog/index.php/2009/06/09/new-drug-approv 
als-on-pace-to-exceed-2008-total.  But see Miho Nagano, Big Pharma Looks for a Fix, 
INVESTOR’S BUS. DAILY, Sept. 29, 2008, at A9 (stating seventeen approvals in 2007).  See infra 
notes 146–49 and accompanying text. 
 2. Gardiner Harris, A New Federal Research Center Will Help to Develop Medicines, N.Y. 
TIMES, Jan. 23, 2011, at A1 (quoting Dr. Francis S. Collins, Director of the National Institutes of 
Health, in a story on the federal government’s decision to launch a billion-dollar drug 
development center to help industry create new pharmaceuticals). 
 3. Alan Poling et al., Pharmaceutical Interventions and Developmental Disabilities, in 
DEVELOPMENTAL   DISABILITIES: ETIOLOGY, ASSESSMENT, INTERVENTION, AND INTEGRATION 
105, 120 (W. Larry Williams ed., 2004).  Poling’s article also states that: 
Few, if any, psychotropic drugs have been adequately evaluated in people with 
developmental disabilities, despite repeated calls for further research. . . . As in years past, 
further research is needed to produce data that will guide physicians in accurately 
matching drugs to patients. . . . The use of single-case research methods may make it 
easier to conduct research, although these methods have been used infrequently in clinical 
psychopharmacology. 
Id. at 119. 
 4. This case study is derived from Dr. Gautreaux’s work with children diagnosed with 
severe learning disabilities.  “Emma” is a fictional name, and identifiers have been excluded to 
protect the family’s privacy.  Similar anecdotal and scientific accounts have been published.  See, 
e.g., CATHERINE MAURICE, LET ME HEAR YOUR VOICE 11–25 (1993). 
 5. See AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS 66–67 (4th ed. 1994) (describing the diagnostic features of “Autistic Disorder”). 
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daughter would never speak, and especially the prognosis that nothing could be 
done to help her.  They researched non-stop and exploited every resource to 
find appropriate educational support.  Their efforts led to entering Emma into a 
program staffed by teachers focusing on her particular situation and taking 
moment-to-moment data on her responses, graphing and analyzing even 
minute components of her day.  Teachers, working in close collaboration and 
constantly comparing and analyzing data, used the detailed information drawn 
from Emma and several other students clinically very similar to her to 
generate, implement, and test—individually and collectively—a  litany of 
highly individualized interventions in an ongoing manner.  Within a little more 
than one year, Emma acquired some functional speech, demonstrated learning 
at increasingly higher rates, showed IQ score improvements, and was 
successfully entered into a program that mainstreamed her with children 
developing according to “typical” indicators.  The interventions—both 
successful and unsuccessful—and accompanying, detailed data were derived 
from the tactics and strategies in the applied behavioral literature.  Most of 
these interventions became the subject of a series of publications in the science 
literature to the benefit of other teachers, children, and the field in general. 
Emma’s story illustrates the cumulative effect yielded from single subject 
research design (“SSRD”), which entails a systematic implementation of the 
scientific method to analyze and treat behavioral problems.6  SSRD, a natural 
science methodology for human clinical research, developed in practice and 
has been addressed in literature for over a half a century in disciplines such as 
behavior analysis, education, physical therapy, and occupational therapy.7  
 
 6. SSRD is explained infra at Part I.B.  For illustrations of SSRD see, JANINE E. JANOSKY 
ET AL., SINGLE SUBJECT DESIGNS IN BIOMEDICINE 81–95 (2009).  “The single subject design is a 
family of designs that share fundamental concepts and methodologies.”  Id. at 9.  It is important 
to note that the literature often commingles single subject studies with “N-of-1” (“number-of-
one”) trials, which may be trials literally involving a single subject.  Most SSRD experiments 
involve focused studies of and between multiple participants.  Gina Green, Single-Case Research 
Methods for Evaluating Treatments for Autism Spectrum Disorders, 8 SPEAKER’S J. 69, 73–74 
(2008) (describing the SSRD method).  For additional background information on SSRD and 
scientific research methods generally, see DAVID H. BARLOW ET AL., SINGLE CASE 
EXPERIMENTAL DESIGNS: STRATEGIES FOR STUDYING BEHAVIOR CHANGE (3d ed. 2009) 
(discussing the origins of SSRD and detailing SSRD methods and issues); MURRAY SIDMAN, 
TACTICS OF SCIENTIFIC RESEARCH: EVALUATING EXPERIMENTAL DATA IN PSYCHOLOGY 2 
(1960) (discussing important points in evaluating scientific research); B.F. SKINNER, THE 
BEHAVIOR OF ORGANISMS: AN EXPERIMENTAL ANALYSIS (1938) (providing the foundation for 
modern-day behavior analysis); John Carey, Medical Guesswork: From Heart Surgery to 
Prostate Care, The Health Industry Knows Little About Which Common Treatments Really Work, 
BUS.WK., May 29, 2006, at 72 (discussing the benefits believed to be provided when using 
“evidence-based” medicine). 
 7. See Robert H. Horner et al., The Use of Single-Subject Research to Identify Evidence-
Based Practice in Special Education, 71 EXCEPTIONAL CHILD. 165, 165–66  (2005); see also 
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With SSRD, evidence-based practices are identified vis-à-vis replication rather 
that the aggregate of results en masse.  SSRD is an alternative to group 
experimental design (“GD”), the global “gold standard” for human clinical trial 
research in drug development.8  GD is based in randomized, parallel, group 
trials.9  While GD typically focuses on ascertaining statistically significant 
variations based upon group averages,10 the core SSRD methodology is to 
repeat comparisons of control and treatment conditions with the same 
 
JOHN O. COOPER ET AL., APPLIED BEHAVIORAL ANALYSIS 201 (2d ed. 2007) (describing 
multiple baseline design as a research tactic for evaluating treatment effects in behavior analysis); 
J. M. JOHNSTON & H. S. PENNYPACKER, STRATEGIES AND TACTICS OF BEHAVIORAL RESEARCH  
296–309 (2d ed. 1993) [hereinafter JOHNSTON & PENNYPACKER, STRATEGIES AND TACTICS] 
(discussing SSRD and GD in the context of behavior analysis); J. M. JOHNSTON & H. S. 
PENNYPACKER, READINGS FOR STRATEGIES AND TACTICS OF BEHAVIORAL RESEARCH 3–7 (2d 
ed. 1993) [hereinafter JOHNSTON & PENNYPACKER, READINGS] (discussing behavior analysis as 
a natural science); ALAN E. KAZDIN, HISTORY OF BEHAVIOR MODIFICATION: EXPERIMENTAL 
FOUNDATIONS OF CONTEMPORARY RESEARCH (1978) (tracing the history of experimentation in 
behavior modification, a field that leans heavily on SSRD type methodologies); Steven C. Hayes, 
Single Case Experimental Design and Empirical Clinical Practice, 49 J. CONSULTING & 
CLINICAL PSYCHOL. 193 (1981) (arguing that SSRD is a good fit for clinical psychology); Mark 
Wolery & Susan R. Harris, Interpreting Results of Single-Subject Research Designs, 62 
PHYSICAL THERAPY 445 (1982) (discussing the interpretation of SSRD results in the context of 
physical and occupational therapy); infra Part I.B.  For thoughtful guidance on the use of SSRD 
in applied psychology, see Neville M. Blampied, Single-Case Research and the Scientist-
Practitioner Ideal, in APA HANDBOOK OF BEHAVIOR ANALYSIS (Gregory J. Madden ed., 
forthcoming 2012) [hereinafter Blampied, Single-Case].  For a tutorial on SSRD, see Neville M. 
Blampied, Univ. of Canterbury, Single-case Research: Useful Tools for 21st Century Applied 
Science, Address at the Society for the Quantitative Analyses of Behavior 34th Annual Meeting 
(May 28, 2011) (PowerPoint presentation on file with the Saint Louis University Law Journal) 
[hereinafter Blampied Presentation].  A video of Professor Blampied’s tutorial presentation is 
available at http://www.sqab.org/tutorials.php. 
 8. JANOSKY ET AL., supra note 6, at 81–82; see infra note 42–43, 86–88 and accompanying 
text. 
 9. JANOSKY ET AL., supra note 6, at 81; see infra note 43 and accompanying text. 
 10. See infra Part I.B (offering a comparative discussion of GD and SSRD).  Although 
averages may be compiled based upon the mode (a variable that occurs the most frequently), the 
mean (the total occurrence divided by the number of subjects), or the median (the occurrence in 
the lies in the middle) of a group under study, group design generally centers on determining 
statistically significant variations between the group that is receiving the treatment and those that 
are not.  See ALAN POLING ET AL., FUNDAMENTALS OF BEHAVIOR ANALYTIC RESEARCH 161–62 
(1995); William W. Rozeboom, Good Science is Abductive, not Hypothetico-Deductive, in WHAT 
IF THERE WERE NO SIGNIFICANCE TESTS? 335, 335–38 (Lisa L. Harlow et al. eds., 1997) 
(discussing the pitfalls of significance testing); STEPHEN T. ZILIAK & DEIRDRE N. MCCLOSKEY, 
THE CULT OF STATISTICAL SIGNIFICANCE 123–130 (2008) (detailing and criticizing the rise of 
statistical significance in psychology research);.  Statistical formulas are derived to account for 
complexity, but they are based upon these averages.  Rozeboom, supra.  Interestingly, 
“[a]veraging across individuals had its origins in a philosophical/religious attempt to remove the 
effects of original sin from measurement of humans.”  Blampied Presentation, supra note 7, at 27. 
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individual or staggered across similar individuals, graph the data on a subject-
by-subject basis, and analyze the results.11  Thus, the individual serves as her 
own control while the variables interacting between the individual and the 
environment are isolated.  Such a finely grained approach enables the 
researcher to obtain valuable information about both the individual and the 
intervention, and more carefully police threatening complications.  This 
research approach has not been utilized in drug development: “Although there 
is a long tradition of employing single subject designs in social science 
research, these designs have only recently been utilized in biomedicine.”12 
This Article proposes law-policy reform of human clinical trials in drug 
development to promote the use of SSRD.  A primary, overarching goal is to 
advance the transition from traditional pharmaceutical R&D, with its focus on 
taking away symptoms, to actually treating the causes of disease—at the 
cellular, genetic, and molecular levels.13  Specifically, the Article challenges 
 
 11. Green, supra note 6, at 74; JANOSKY ET AL., supra note 6, at 81; DAVID L. MORGAN & 
ROBIN K. MORGAN, SINGLE-CASE RESEARCH METHODS FOR THE BEHAVIORAL AND HEALTH 
SCIENCES 27–30 (2009); Jaan Valsiner, Where is the Individual Subject in Scientific Psychology?, 
in THE INDIVIDUAL SUBJECT AND SCIENTIFIC PSYCHOLOGY 11  (Jaan Valsiner ed., 1986).  SSRD 
is discussed in detail infra at Part I.B.  For an excellent, accessible summary of SSRD 
methodology, see generally Blampied Presentation, supra note 7.  For discussion of SSRD in the 
context of applied psychology, see Blampied, Single-Case, supra note 7. 
 12. JANOSKY ET AL., supra note 6, at 81; see also Green, supra note 6, at 69. 
 13. See infra Part II.B.  This Article focuses on human clinical trials, not basic (“bench”) 
studies.  Reflective of the vast complexity and dynamism of human genetics—an estimated 
23,000 genes responsible for all human variability, and the intense, ongoing interface of genes 
and environmental factors in human health—and the nascent state of genetic science at this time, 
there is tremendous dependence on group studies at the very beginning of the drug development 
continuum.  American Health Lawyers Association’s Advisory Council on Racial and Ethnic 
Diversity, Patient-Tailored Medicine Part One: The Impact of Race and Genetics on Medicine, J. 
HEALTH & LIFE SCI. L., Oct. 2008, at 1, 7 [hereinafter Patient-Tailored Medicine Part One]; 
American Health Lawyers Association’s Advisory Council on Racial and Ethnic Diversity, 
Patient-Tailored Medicine, Part Two: Personalized Medicine and the Legal Landscape, J. 
HEALTH & LIFE SCI. L., Jan. 2009 at 1, 5–7 [hereinafter Patient-Tailored Medicine Part Two].  A 
rough map of the human genome determined “active” was completed just years ago (2003), and 
efforts to purify that map and to fully decode the human genome are still underway.  Human 
Genome Project Information, U.S. DEPT. OF ENERGY, http://www.ornl.gov/sci/techresources/Hu 
man_Genome/home.shtml (last updated July 25, 2011).  Now scientists in the field of epigenetics 
are studying the “other human genome”—heritable changes in gene function that occur without a 
change in DNA.  See Gary Felsenfeld, A Brief History of Epigenetics, in EPIGENETICS 16 (C. 
David Allis et al. eds., 2007); Adrian Bird, Perceptions of Epigenetics, 447 NATURE 396, 396 
(2007); see generally JAMES A. GOODRICH & JENNIFER F. KUGEL, BINDING AND KINETICS FOR 
MOLECULAR BIOLOGISTS (2007) (discussing qualitative measurements of biological binding 
reactions, “which are the fundamental building blocks of all complex biological systems”).  For a 
richer discussion of the genome, see ERIC H. DAVISON, THE REGULATORY GENOME: GENE 
REGULATORY NETWORKS IN DEVELOPMENT AND EVOLUTION (2006).  For further discussion of 
epigenetics, see the articles contained in Epigenetics, 293 SCI. 1063–106 (2001), and NOVA: 
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the FDA’s extensive reliance on the GD model, which has governed clinical 
research since not too long after enactment of the Food, Drug and Cosmetic 
Act in 1938,14 and suggests law-policy reforms to increase SSRD studies in 
drug development.  A major premise is that regulation of human clinical trials 
should be responsive to the governing science, and SSRD emphasizes the 
reality of human variability15 in a manner in sync with contemporary genetic 
science and the actual practice of medicine.16  The core message is that relying 
on data generated through GD alone—again, group averages compiled through 
statistical analysis to test hypotheses—risks predicting little about the actual 
impact of prescription medicines on individual patients at the detriment of 
ongoing and future drug development, to the loss of multiple tens of millions 
of living patients waiting for treatments, who are suffering from ongoing, 
seriously debilitating, and even life-threatening human health ailments.17  Such 
 
Epigenetics (PBS television broadcast July 24, 2007), available at http://www.pbs.org/wgbh/no 
va/sciencenow/3411/02.html.  In sum, at the base level of genetic science, comparisons are made 
between multiple individuals at the genetic level, at times entire populations (“biobanks”), to sort 
through this vast universe of variables and identify points for study.  See generally Symposium, 
Regulation of Biobanks, 33 J.L. MED. & ETHICS 1 (2005) (offering articles discussing biobanks 
and biobanking issues); Symposium, Proceedings of “The Genomics Revolution? Science, Law 
and Policy”, 66 LA. L. REV. (Special Issue) 1 (2005) [hereinafter Genomics Revolution] (offering 
articles discussing the necessity for biobanking to meet the needs of genomics research); see also 
Michael J. Malinowski, Law, Policy, and Market Implications of Genetic Profiling in Drug 
Development, 2 HOUS. J. HEALTH L. & POL. 31 (2002) (noting the law, policy, and market 
implications of pharmacogenomics).  Lars Noah, The Coming Pharmacogenomics Revolution: 
Tailoring Drugs to Fit Patients’ Genetic Profiles, 43 JURIMETRICS J. 1, 7–11 (2002) (discussing 
the potential for pharmacogenomic research to enhance pharmaceutical therapies). Therefore, this 
Article appreciates the distinction between genetic studies at the molecular level from human 
clinical trials to treat individuals, and the discussion centers on the latter.  Comparing the utility 
of GD and SSRD at the base level of drug development is beyond the scope of this Article. 
 14. “The first of the so-called miracle drugs, Sulfanilamide, led to the adoption of the 
Federal Food, Drug, and Cosmetic Act of 1938 which emphasized premarketing safety of drugs, 
based on scientifically designated animal and clinical studies.”  STEVEN E. PEGALIS, AMERICAN 
LAW OF MEDICAL MALPRACTICE § 17:13 (3d ed. 2005). 
 15. It is important to note that, while “human variability” is assumed and considered innate 
to humans in group experimental design, in SSRD human variability is considered external and is 
able to be controlled by accounting for extraneous variables.  See infra Part I.B. 
 16. See Patient-Tailored Medicine Part One, supra note 13, at 7: see generally Genomics 
Revolution, supra note 13 (offering articles discussing contemporary genetic science and issues in 
genomics).  Genetic specificity in contemporary biopharmaceutical R&D is addressed infra at 
Part II.B. 
 17. As observed by other commentators in the context of patient-tailored medicine and race-
based genetics research: 
To predict therapeutic outcomes in individual patients, drug makers rely on statistical 
analyses of a targeted population’s response to the medication in question. Thus, a 
practitioner’s choice of drug often is based on population averages.  Therefore, the current 
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a reliance on this type of analysis may conceivably mask potentially effective 
treatments for individuals and life-threatening complications for others. 
A major focus of discussion is the nexus between the regulation of drug 
development and the delivery of health care.  Under the present law-policy 
scheme, drug review is too lenient,18 practical yet sophisticated understanding 
of new pharmaceuticals is too limited, and market approval invites excessive 
off-label use—an approach that muddles clinical care with clinical research 
excessively, and exacerbates the unpredictability of prescription medications.19  
 
method of developing drug therapy focuses on large patient populations as groups, 
irrespective of the potential for individual, genetically-based differences in drug response. 
Patient-Tailored Medicine Part One, supra note 13, at 7.  The extent to which drug sponsors have 
been permitted to generalize over human variation in clinical research is extraordinary.  For 
example, throughout most of the twentieth century, women and children typically were excluded 
from the groups studied to bring many of our familiar pharmaceuticals to market—including 
pharmaceuticals for conditions that impact women and children, such as asthma and heart disease.  
See Sarah K. Keitt, Sex & Gender: The Politics, Policy, and Practice of Medical Research, 3 
YALE J. HEALTH POL’Y L. & ETHICS 253, 253 (2003).  The rationale was to work to avoid groups 
deemed “protected” under federal regulations to protect human subjects—including women, the 
unborn, and children—and subject to more scrutiny, coupled with failure to appreciate the 
hormonal and other biological differences between men and women, adults and children, or the 
strategic choice to avoid complicating trials with factors such as the female hormonal cycle, 
menopause, and puberty.  Id. at 254–55; Karen H. Rothenberg, Gender Matters: Implications for 
Clinical Research and Women’s Health Care, 32 HOUS. L. REV. 1201, 1206–10 (1996). 
Accordingly, out of necessity, doctors prescribed medicines on the market to treat women and 
children in spite of a dearth of data about those uses.  For example, the doses for children have 
been adjusted at doctor discretion based upon weight—similar to veterinary practice today.  See 
Barbara A. Noah, Just a Spoonful of Sugar: Drug Safety for Pediatric Populations, 37 J.L. MED. 
& ETHICS 280, 281–82 (2009).  The 1993 NIH Revitalization Act requires inclusion of women in 
Phase III clinical studies and gender-based analysis of research results.  National Institutes of 
Health Revitalization Act of 1993, Pub. L. No. 103-43, §131, 107 Stat. 122, 133–35 (codified at 
42 U.S.C. § 289a-2 (2006)).  The Best Pharmaceuticals for Children Act (“BPCA”) codified 
patent extension incentives for drug sponsors to include children and created a trust fund for the 
FDA to do the same when drug sponsors refuse—conducting its own trials directly or through 
contracted third parties.  See Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 
Stat. 1408 (2002) (codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.). 
 18. In addition to the limitations of GD addressed throughout this Article, the efficacy 
standard for market approval based upon that data is to be better than a placebo or sugar pill, 
meaning to be better than nothing.  See infra note 58 and accompanying text. 
 19. See infra Part III.A.  Congress has responded to the problem, but this Article questions 
its fix through the Food and Drug Administration Amendments Act of 2007 (“FDAAA”) because 
of the ongoing fundamental reliance on GD.  See infra notes 23–25 and accompanying text.  
“[N]either Congress nor the FDA has attempted to regulate the off-label use of drugs by doctors 
and consumers.  A physician may prescribe a legal drug to serve any purpose that he or she deems 
appropriate, regardless of whether the drug has been approved for that use by the FDA.”  Wash. 
Legal Found. v. Henney, 202 F.3d 331, 333 (D.C. Cir. 2000).  Off-label use of pharmaceuticals is 
generally accepted in the medical community and commonly practiced.  Wash. Legal Found. v. 
Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998), vacated in part on other grounds sub nom. 
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Ultimately, the medical profession exercises expansive prescription discretion, 
on and off FDA-approved labels, to sort through the actual safety, efficacy, and 
peculiarities of a drug patient-by-patient, and over time—typically years—after 
the drug is on the market.20  As documented in one empirical study, “Off-label 
prescribing is very common in all areas of medicine.  It is not uncommon for a 
drug to be prescribed more often off-label than on-label. . . . Indeed, 80 percent 
to 90 percent of pediatric patient regimens involve at least one off-label 
prescription.”21  Ironically, off-label usage has been common practice for 
individuals with developmental disabilities and autism, while some physicians 
do not always recognize applied behavior analysis as a validated treatment for 
autism due to the apparent dearth of large scale GD studies.22 
Congress has recognized and addressed the problem through sweeping 
legislation known as the Food and Drug Administration Amendments Act of 
2007 (“FDAAA”).23  The methodology of FDAAA is to “augment premarket 
clinical studies” and try to cull more from resulting data “with new sources of 
evidence about the risks and benefits of drugs,” but the Act does not change 
 
Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000) (observing that “off-label use of 
FDA-approved drugs by physicians is an established aspect of the modern practice of medicine”); 
see Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 350 (2001) (noting that off-label use 
of medication is not only accepted in the medical community, but a “necessary corollary of the 
FDA’s mission to regulate . . . without directly interfering with the practice of medicine”). 
 20. The same often is true with new medical devices and procedures.  An illustrative 
example of this point is the debate over when women should have mammograms.  After decades 
of relying upon group numbers to strongly encourage all women over the age of forty years to 
have mammograms annually, the U.S. Preventive Services Task Force, based upon actual patient 
experience with the technology, now discourages the presumption and emphasizes the importance 
of a case-by-case, physician-patient, individualized approach.  Danielle Dellorto, Task Force 
Opposes Routine Mammograms for Women Age 40–49, CNN HEALTH (Nov. 16, 2009), http://ar 
ticles.cnn.com/2009-11-16/health/mammography.recommendation.changes_1_routine-mam 
mograms-mammography-task-force?_s=PM:HEALTH.  For more information on the task force 
and its projects, see U.S. Preventive Services Task Force, U.S. DEPT. OF HEALTH & HUMAN 
SERV., http://www.ahrq.gov/clinic/uspstfix.htm (last visited Dec. 29, 2011). 
 21. Daniel B. Klein & Alexander Tabarrok, Do Off-Label Drug Practices Argue Against 
FDA Efficacy Requirements? A Critical Analysis of Physicians’ Argumentation for Initial 
Efficacy Requirements, 67 AM. J. ECON. & SOC. 743, 744, 755 (2008).  As observed by these 
authors, “Most cancer and AIDS patients are given drugs that are not FDA certified for the 
prescribed use.  In a large number of fields, a majority of patients are prescribed at least one drug 
off-label.”  Id. at 744 (citations omitted). 
 22. See Poling, supra note 3, at 119–20; Autism Spectrum Disorders: Treatment Options, 
NAT’L INST. OF MENTAL HEALTH, http://www.nimh.nih.gov/health/publications/autism/treat 
ment-options.shtml (last updated July 22, 2009).  Off-label use is extremely pervasive in 
pediatrics, and data for the pharmaceutical treatment of behavior disorders in people with 
developmental disabilities is grossly insufficient.  See Klein & Alexander, supra note 21, at 755; 
Poling, supra note 3, at 119–20. 
 23. Pub. L. No. 110-85, 121 Stat. 823 (codified as amended in scattered sections of 21 
U.S.C.). 
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reliance on GD as the gold standard in drug development.24  Rather, the core 
methodology of FDAAA is to do more with GD—in essence, to rely on it 
more.25  Continued over-reliance on GD in human clinical studies coupled with 
extensive medical community discretion to essentially experiment on patients 
without systematically contributing to the research base—as opposed to 
clinical researchers experimenting on research subjects under human subject 
protections and direct FDA oversight—threatens to perpetuate a crude working 
standard for prescription medications as they enter the market and for years 
thereafter.  This regulatory approach is increasingly unacceptable in an age of 
genetic science.26 
This Article begins by profiling GD in human clinical trials—again, the so-
called gold standard and the cornerstone of the law-policy rubric governing 
market approval for human medicinal products.27  Tremendous reliance on GD 
has been reinforced globally through the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use (“ICH”) standard sharing.28  Part I then introduces SSRD in an 
interdisciplinary, comparative manner through discussion that draws from a 
debate over GD and SSRD in human clinical studies developed in another 
health care context—the field of applied behavior analysis (“ABA”).29  
Specifically, the Comprehensive Application of Behavior Analysis to 
Schooling Program (“CABAS®”) at Columbia University’s Teachers College 
has utilized SSRD in research with and treatment of children with behavioral 
conditions and often severe learning disabilities, many labeled “autistic,” and, 
 
 24. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and 
Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME L. REV. 419, 420, 434 (2010) 
[hereinafter Evans, Seven Pillars].  For a thorough discussion of the FDAAA, see id., and Barbara 
J. Evans, Authority of the Food and Drug Administration to Require Data Access and Control 
Use Rights in the Sentinel Data Network, 65 FOOD & DRUG L.J. 67 (2010) [hereinafter Evans, 
Authority]. 
 25. See Evans, Seven Pillars, supra note 24, at 425. 
 26. For discussion of the impact of genetic science on drug development methodology and 
the associated potential to raise precision, see infra Part II.B. 
 27. See supra notes 8–9 and accompanying text. 
 28. Several guidances for clinical trials originally developed by the ICH have been adopted 
by the FDA and published in the Federal Register.  See, e.g., International Conference on 
Harmonisation; Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583 (Sept. 
16, 1998); International Conference on Harmonization; Good Clinical Practice: Consolidated 
Guideline, 62 Fed. Reg. 25,692 (May 7, 1997); see generally ICH Guidance Examines Statistical 
Principles to Support Clinical Research, GUIDE TO GOOD CLINICAL PRAC. NEWSL. (Thompson 
Publishing Group, Inc., Wash., D.C.), Nov. 1998, at 5, available at 6 No. 2 CLINPRAC-NWL 5 
[hereinafter ICH Guidance Examines].  For general information about the ICH, visit its official 
website, http://www.ich.org (last visited Dec. 29, 2011). 
 29. See COOPER ET AL., supra note 7, at 201–24 (discussing a popular research method in 
applied behavior analysis); JOHNSTON & PENNYPACKER, READINGS, supra note 7, at 16–17; 
JOHNSTON & PENNYPACKER, STRATEGIES AND TACTICS, supra note 7, at 296–309. 
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more recently, neuro-typical children.30  This is a highly protected group under 
the regulations to protect human subjects31—one that has been too often 
overlooked and avoided in clinical research for drug development and yet 
routinely prescribed medications that reach the market.32  CABAS®, with a 
legacy of three decades of research and an international network of schools and 
graduates working in the field, has challenged the preexisting norms of heavy 
reliance on GD in clinical research and generated significant research 
accomplishments and documented treatment interventions.33  In addition to the 
shared context of clinical research, treatment for patients with developmental 
disabilities depends heavily—arguably, often too heavily—on utilization of 
prescription medicines made available through the drug development process 
without data sufficient for physicians to match drugs and patients.34  These 
practices, in addition to raising cautionary concerns regarding unknown side 
effects, may also lead to an unsubstantiated yet alluring false efficacy. 
Part II frames ongoing disappointments and frustrations with contemporary 
drug development and challenges the entrenched reliance on GD.  Specifically, 
this Part questions continued dependence upon mathematical abstracts that, 
although representative of the group collectively, may say nothing decisive 
about members of the group individually, let alone broad populations of 
patients with health care needs outside the group.  The discussion concludes 
that the core regulatory process to put drugs on the market lingers from the 
past and is disconnected from the patient-centered nature of the practice of 
medicine and the science disciplines that dominate today’s innovative 
biopharmaceutical R&D.  Part III proposes a regulatory overhaul of clinical 
research to modify the gold standard through utilization of SSRD.  This 
proposal draws from past efforts by Congress and the FDA to shape clinical 
trial research through both direct mandates and commercial incentives, 
 
 30. R. Douglas Greer & Dolleen-Day Keohane, A Real Science and Technology of 
Education, in EVIDENCE-BASED EDUCATIONAL METHODS 23, 37–38 (Daniel J. Moran & 
Richard. W. Malott eds., 2004) [hereinafter Greer & Keohane, Real Science]; R. Douglas Greer et 
al., The Effects of the Verbal Developmental Capability of Naming on How Children Can Be 
Taught, 1 ACTA DE INVESTIGACIÓN PSICOLÓGICA 23, 26–27 (2011); R. Douglas Greer & 
Dolleen-Day Keohane, The Evolution of Verbal Behavior in Children, BEHAV. DEV. BULL. 31 
(2005), reprinted in 1 J. SPEECH LANGUAGE PATHOLOGY & APPLIED BEHAV. ANALYSIS 111, 
112–13 (2006). 
 31. 45 C.F.R. §§ 46.401–.409 (2010) (establishing children as one of the protected groups 
within overall human subject protection regulations).  For discussion of the absence of children in 
drug development research, see infra notes 248–268. 
 32. See supra note 17. 
 33. See Greer & Keohane, Real Science, supra note 30, at 37–41. 
 34. See supra note 17; Poling, supra note 3, at 119. 
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including the Best Pharmaceuticals for Children Act (“BPCA”)35 and the 
Orphan Drug Act (“ODA”).36 
I.  THE “GOLD STANDARD” IN HUMAN CLINICAL RESEARCH AND THE SSRD 
ALTERNATIVE 
The following discussion summarizes the evolution of GD as the gold 
standard for clinical research and drug approval with a focus on the 
accompanying law-policy rubric that promotes it.37  The discussion then 
profiles SSRD as an alternative natural science research methodology for 
human clinical research that, although increasingly recognized in biomedicine 
in recent years, remains highly underutilized in biopharmaceutical R&D.38 
A. The Science and Law-Policy Rubric for Human Clinical Research 
The law-policy surrounding human clinical trials reflects the regulatory 
role the FDA has evolved into during the decades after enactment of the Food, 
Drug, and Cosmetic Act of 1938 (“FDCA”).39  The FDCA bestowed the 
Agency with the powers to assume a market gatekeeper role—the authority to 
examine, question, and evaluate the clinical utility of drugs.40  Still, prior to 
1970, the Agency made law primarily by pursuing judicial enforcement of 
statutory standards.41  Subsequently, the Agency has shifted in the direction of 
an administrative law-policy approach—exercising its capacity as product 
reviewer and rule-maker—and has raised the burden on drug sponsors to earn 
market approval.  As observed by authors Hutt, Merrill, and Grossman, “Faced 
 
 35. Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408 (2002) 
(codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.). 
 36. Orphan Drug Act, Pub. L. No. 97-414, § 2, 96 Stat. 2049, 2049–51 (1983) (codified as 
amended in scattered sections of 21 U.S.C. and 42 U.S.C.). 
 37. See infra notes 43–44, 92–94 and accompanying text. 
 38. JANOSKY ET AL., supra note 6, at 81. 
 39. Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 
(codified as amended at 21 U.S.C. §§ 301–399 (2006)) (“FDCA”).  The FDCA has been amended 
more than 100 times.  Peter Barton Hutt, A Historical Introduction, 45 FOOD DRUG COSM. L.J. 17 
(1990), as reprinted in PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 4 (3d ed. 2007).  The 
Agency we now know as the FDA was created by the Federal Food and Drugs Act of 1906.  
Federal Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat. 768 (repealed 1938); John P. 
Swann, About FDA: FDA’s Origins, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/About 
FDA/WhatWeDo/History/default.htm (last visited Dec. 29, 2011).  The Act prohibited 
adulterated and misbranded food and drugs and introduced an administrative enforcement clause 
to enable implementation.  Paul Hyman, U.S. Food and Drug Law and FDA—A Historical 
Background, in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 21 (Kenneth 
R. Piña & Wayne L. Pines eds., 1st ed. 1998). 
 40. Richard A. Merrill, The Architecture of Government Regulation of Medical Products, 82 
VA. L. REV. 1753 (1996), as reprinted in HUTT ET AL., supra note 39, at 5. 
 41. HUTT ET AL., supra note 39, at viii. 
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with increasingly complex substantive issues and a growing number of firms 
making regulated products, FDA turned toward rulemaking as the principal 
technique for defining legal requirements.  The agency attempted to resolve 
most of the major issues it confronted through administrative, rather than court, 
action.”42  The FDA, as product reviewer and market gatekeeper, has been 
responsive to clinical trial data of effectiveness generated through 
implementation of the GD gold standard—randomized, parallel, group clinical 
trial designs.43  The standard has been adopted globally, as recognized by the 
ICH in E9 Statistical Principles for Clinical Trials.  The ICH issued E9 in 
1998 to harmonize statistical methodologies used to support marketing 
applications.44  The ICH serves as an advisory body for drug harmonization for 
the European Union (“EU”) through the European Medicines Agency 
(“EMA”), the United States through the FDA, and Japan through the Ministry 
of Health, Labor, and Welfare.45  In 2008, the ICH developed technical 
requirements for registration of pharmaceuticals for human use.46  The 
requirements defined key terms in the discipline of pharmacogenomics, 
including pharmacogenetics, genomic biomarkers, and genomic data, and 
provided sample drug coding categories.47  The intent was “to develop 
 
 42. Id. 
 43. Id. at 624; JANOSKY ET AL., supra note 6, at 81–82; Carey, supra note 6, at 77. 
 44. See generally ICH Guidance Examines, supra note 28; International Conference on 
Harmonisation; Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583, 49,584 
(Sept. 16, 1998).  The ICH has developed shared scientific standards for clinical data and good 
clinical practice.  Michael J. Malinowski, Ethics in a Global Biopharmaceutical Environment, 5 
SANTA CLARA J. INT’L L. 57, 70–71 (2006), http://www.scujil.org/sites/default/files/volumes/v5_ 
MalinowskiArticle.pdf.  For information about the ICH, visit its official website, 
http://www.ich.org (last visited Dec. 29, 2011).  Six conferences have been held to date, and a 
seventh (the “ICH7 Conference”) was scheduled to take place March 29–30, 2006, in Vienna, 
Austria, but was cancelled.  ICH Steering Committee Meeting Summary 7 (June 5–8, 2006), 
available at http://www.ich.org/uploads/media/SC_Report_Yokohama_2006.pdf.  The 
organization itself, with representatives from both government and industry, operates in an 
ongoing manner.  For an international extension of this Article that directly addresses the ICH, 
see Michael J. Malinowski & Grant G. Gautreaux, All that is Gold Does Not Glitter in Human 
Clinical Research: A Law-Policy Proposal to Brighten the Global “Gold Standard” for Drug 
Research and Development, 45 CORNELL J. INT’L LAW (forthcoming 2012). 
 45. Vision, ICH, http://www.ich.org/about/vision.html (last visited Dec. 29, 2011). 
 46. See International Conference on Harmonisation; Guidance on E15 Pharmacogenomics 
Definitions and Sample Coding, 73 Fed. Reg. 19,074 (Apr. 8, 2008). 
 47. Id. at 19,075.  Pharmacogenomics and pharmacogenetics are defined and discussed infra 
at notes 48, 135, and 238 and accompanying text.  In simplest terms, genomics is the science of 
genetic expression and its influence on human health.  Genomics and Health, CTRS. FOR DISEASE 
CONTROL & PREVENTION, http://www.cdc.gov/genomics/public/index.htm (last updated Apr. 26, 
2010).  The discipline has become prevalent at the forefront of drug development, with 
completion of the map of the human genome announced in 2003.  See supra note 13 and 
accompanying text.  A biomarker is “[a] biochemical feature or facet that can be used to measure 
the progress of disease or the effects of treatment.”  Definition of Biomarker, MEDICINENET, 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2012] DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY? 377 
harmonized approaches to drug regulation” and “to ensure that consistent 
definitions of terminology are being applied across all constituents of the 
[ICH],” as well as the “integration of the discipline of pharmacogenomics 
[(“PG”)] and pharmacogenetics into the global drug development and approval 
processes.”48  In 2010, the ICH developed requirements for the context, 
structure, and format of voluntary biomarker submissions from PG research in 
order to create a “harmonized recommended structure for biomarker 
qualification” that will allow for consistency of applications and will “facilitate 
discussions with and among regulatory authorities.”49  Between the three 
regulatory entities enveloped in the ICH, all three adhere to these standards, 
but at this point no standards have been developed to integrate PG into 
mainstream healthcare. 
The resulting quid pro quo for market access is data generated through GD 
in four phases (sometimes classified as five) of clinical trials.50  Phase I trials 
generally are conducted in tens of healthy volunteers for up to a month with 
the objective of making the transition from animal to human participants 
through research on toxicity and a showing of safety.51  Minimum doses are 
administered, and the healthy status of participants enhances the transparency 
of their impact.52  With a focus on safety, the core objective of these trials is to 
assess the metabolic and pharmacological actions of the drug candidate in 
 
http://www.medterms.com/script/main/art.asp?articlekey=6685 (last reviewed Apr. 27, 2011).  
The FDA provides a table of genomic biomarkers used in approved drug labels at Table of 
Pharmacogenomic Biomarkers in Drug Labels, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ 
Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (last visited Dec. 29, 
2011). 
 48. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics 
Definitions and Sample Coding, 73 Fed. Reg. at 19,075. 
 49. CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN., GUIDANCE 
FOR INDUSTRY: E16 BIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT 
DEVELOPMENT: CONTEXT, STRUCTURE, AND FORMAT OF QUALIFICATION SUBMISSIONS 1 & n.1, 
2 (2011). 
 50. See infra notes 51–64 and accompanying text.  Deviations from the standard drug 
approval clinical trial process described are granted for unusual circumstances, such as trials on 
drug candidates for very small patient disease groups and those for highly innovative therapeutics 
for presently untreatable conditions that will expose study participants to extremely high levels of 
risk.  The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. FOOD & 
DRUG ADMIN., http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm (last 
visited Dec. 29, 2011); see  infra notes 268–69 and accompanying text; see also Risk and 
Responsibility: The Roles of FDA and Pharmaceutical Companies in Ensuring the Safety of 
Approved Drugs, Like Vioxx: Hearing Before the H. Comm. on Gov’t Reform, 109th Cong. 24–25 
(2005) (statement of Steven Galson, Acting Director Center for Drug Evaluation and Research) 
(outlining the pre-market approval process). 
 51. See 21 C.F.R. § 312.21(a) (2011). 
 52. HUTT ET AL., supra note 39, at 630–31. 
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humans, and to identify side effects while increasing doses.53  Phase I trials 
also may garner early evidence of effectiveness.54  Phase II trials involve 
hundreds of participants drawn from the target disease group and span several 
months.55  The objectives are to study the effectiveness of the new treatment, 
to determine short-term side effects and overall risks associated with the drug, 
and to develop advanced dosage criteria.56  Phase III typically encompasses 
thousands of disease group participants at multiple sites with the goals of 
balancing safety and efficacy, to refine dosage, and establish overall 
effectiveness against a placebo (sugar pill) or other control.57 
The data generated in Phase III shapes applications for market access.  The 
baseline standard for market approval is to outperform a placebo on efficacy, 
perhaps just by a percentage point or two, with a showing of tolerable safety in 
a defined population.58  Once biopharmaceuticals reach the market, the 
medical community has broad discretion to use them off-label—and does so 
aggressively.59  The FDA continues to regulate pharmaceuticals post-market 
approval through Phase IV follow-on trials that probe lingering questions and 
strive to perfect clinical use, that is, to develop additional details about the 
product’s safety and efficacy.60  Congress has attempted to shift traditional 
 
 53. 21 C.F.R. § 312.21(a). 
 54. Id.  With an increase of innovative new drug candidates, Phase I trials have been 
modified in recent years to occasionally include efficacy testing in terminally ill patients 
particularly where there are nonexistent or insufficient existing treatments, thereby comingling 
traditional Phases I and II and clinical research and care.  See Jamie L. Aldes, Note, The FDA 
Clinical Trial Process: Effectuating Chance in the Regulatory Framework Governing Clinical 
Trials to Account for the Historical Shift from “Traditional” to “New” Phase I Trials, 18 
HEALTH MATRIX 463, 473–74 (2008). 
 55. Aldes, supra note 54, at 471. 
 56. 21 C.F.R. § 312.21(b) (2011). 
 57. Id. at § 312.21(c).  Stuart R. Cohn & Erin M. Swick, The Sitting Ducks of Securities 
Class Action Litigation: Bio-Pharmas and the Need for Improved Evaluations of Scientific Data, 
35 DEL. J. CORP. L. 911, 918 (2010); Geoffrey M. Levitt, The Drugs/Biologics Approval Process, 
in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION, supra note 39, at 101.  As 
discussed infra at note 79 and in the accompanying text, over the last five years, typical Phase III 
trials have expanded from 5,000 to 20,000 subjects and their cost has doubled to surpass $100 
million.  Nagano, supra note 1. 
 58. 21 C.F.R. § 314.126(a) (2010); Aldes, supra note 54, at 468.  See generally W. John 
Thomas, The Vioxx Story: Would it have Ended Differently in the European Union?, 32 AM. J. L. 
& MED. 365 (2006) (discussing the approval of Vioxx under the American drug approval process 
and contrasting the U.S. approval process with that of the European Union). 
 59. See supra notes 19–22 and infra note 115–19 and accompanying text. 
 60. Aldes, supra note 54, at 472; see 21 C.F.R. § 314.80 (2011); HUTT ET AL., supra note 
39, at 734–38. 
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Phase IV trials into premarket studies through the FDAAA.61  Phase IV studies 
have been largely observational and centered on post-marketing surveillance to 
detect and define previously unknown or inadequately quantified adverse 
reactions and related risk factors.62  In recent years, these studies often have 
distinguished defined demographic groups that may have been overlooked as a 
focus point during the trials that put the drugs on the market.63  Areas of 
inquiry may involve formulation evaluations, dosages, the durations of 
treatment, and interactions with other medications.64 
A major trend since implementation of the Food and Drug Administration 
Modernization Act of 1997 (“FDAMA”) has been to err in favor of putting 
new drugs on the market on a watch-and-see basis to introduce access for 
patients in need, albeit conditioned with follow-on studies—often referred to as 
506B studies.65  This approach is consistent with expansion of the FDA’s 
mission under FDAMA to include efficiency, along with efficacy and safety, 
for new drug approvals.66  Unfortunately, the FDA has been lax in enforcing 
these post-market study conditions.67 
 
 61. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, § 901, 
121 Stat. 823, 922–43; Evans, Seven Pillars, supra note 24, at 477; see generally Evans, 
Authority, supra note 24; Malinowski & Gautreaux, supra note 44. 
 62. Post-marketing surveillance is sometimes referred to as “Phase V” trials.  See Aldes, 
supra note 54, at 472 (“Phase V trials monitor the effects of the drugs as reported by physicians, 
survey data, and discover new uses for the drug.”). 
 63. See Patient-Tailored Medicine Part Two, supra note 13, at 16–17 (discussing lack of 
minority participants in clinical trials). 
 64. OFFICE OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & HUMAN SERVS., FDA’S 
MONITORING OF POSTMARKETING STUDY COMMITMENTS 1 (2006). 
 65. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 
§130, 111 Stat. 2296, 2231–32 (codified at 21 U.S.C. 356b).  Section 506B of FDAMA, the 
provision that promotes this presumption in favor of market approval, is codified under 21 U.S.C. 
§ 356b. That same section provides FDA enforcement authority for 506B studies.  21 U.S.C. § 
356b(d)–(e) (2006).  See also OFFICE OF INSPECTOR GEN., supra note 64, at 1, 2–3 (discussing 
506B post-marketing studies). 
 66. Christopher D. Zalesky, Considering Changes to CMS’s National Coverage Decision 
Process: Applying Lessons Learned From FDA as a Regulator of Access to Healthcare 
Technology, 57 FOOD & DRUG L.J. 73, 86 (2002); James L. Zelenay, Jr., The Prescription Drug 
User Fee Act: Is a Faster Food and Drug Administration Always a Better Food and Drug 
Administration?, 60 FOOD & DRUG L.J. 261, 295 (2005) (“PDUFA II [enacted in conjunction 
with FDAMA] shifted the agency’s focus from one based solely on protecting the public from 
unsafe and ineffective products, possibly at the cost of expediency, to one that must balance this 
interest in safety with an interest in providing patients with speedy access to new drugs.”). 
 67. See U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-06-402, DRUG SAFETY: 
IMPROVEMENT NEEDED IN FDA’S POSTMARKET DECISION-MAKING AND OVERSIGHT PROCESS 
18–23 (2006) (finding the FDA lacks a clear and effective process for post-market drug safety 
decision making); INST. OF MED., THE FUTURE OF DRUG SAFETY: ACTION STEPS FOR CONGRESS 
1 (2006) (noting FDA’s lack of clear authority to enforce compliance). 
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FDA regulations and standards for clinical trial study design distinguish 
exploratory trials from confirmatory trials and hold the former to more rigid 
standards.68  With the most common study design, parallel group experimental 
design, participants are randomized to one or more trial arms, and each arm is 
allocated a different treatment.69  Ideally for the purposes of generating and 
collecting data both for safety and efficacy, GD comparisons are drawn 
between a group of participants taking the drug candidate and another 
administered a placebo to show statistically significant differences between 
group mean scores.70  Double-blinding (neither the administering physician nor 
the participants know who actually is receiving the drug candidate) is used to 
check the risk of bias.71  However, in practice, it tends to be much more 
complicated to incorporate participants’ access to existing treatments into the 
studies.  Research subjects are administered the drug candidate coupled with 
an existing standard-of-care treatment.72  Comparisons are made with groups 
 
 68. As explained under the ICH E9 Guidance, which incorporates FDA standards, 
exploratory trials “cannot be the basis of the formal proof of efficacy, although they may 
contribute to the total body of relevant evidence.”  International Conference on Harmonisation; 
Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583, 49,587 (Sept. 16, 
1998).  The Guidance “suggests that sponsors conducting confirmatory trials estimate the size of 
the effects of the investigational product and relate the estimate to actual clinical significance.  
Because the hypothesis to be tested is largely based on clinical results and because a single 
confirmatory trial may be used to establish efficacy, adherence to the protocol and standard 
operating procedures is a must . . . .”  ICH Guidance Examines, supra note 28. 
 69. Green, supra note 6, at 70–71. 
 70. See id.  Testing against a placebo is testing against nothing, which is the extreme 
comparison—the greatest means to document efficacy data in patient group research.  See id. 
 71. International Conference on Harmonisation; Guidance on Statistical Principles for 
Clinical Trials, 63 Fed. Reg. at 49,587.  The E9 Guidance recommends using double-blinding 
where investigational “treatments are prepacked with a randomization schedule, and supplied to 
the trial center(s) labeled only with the subject number and the treatment period so that no one 
involved in the conduct of the trial is aware of the specific treatment allocated to any particular 
subject.”  Id.  According to the Guidance, blind breaking should only occur when the trial 
subject’s physician deems it necessary; if blind breaking does occur, it “should be reported and 
explained at the end of the trial.”  Id.  A trend increasing in recent years is for study participants 
to use modern technology to remove their half of the double-blind—from internet access to 
communication with other subjects via patient group chat rooms and blogs that enable collective 
information and comparisons, to sending blood samples to independent laboratories to discern 
directly whether they are getting the drug candidate.  LAWRENCE M. FRIEDMAN ET AL., 
FUNDAMENTALS OF CLINICAL TRIALS 87 (3d ed. 1996). 
 72. Ethics norms for domestic U.S. research, as embodied in the Common Rule, ban denial 
of access to existing treatments with instances of seriously debilitating and life-threatening 
conditions.  See Paul Litton & Franklin G. Miller, A Normative Justification for Distinguishing 
the Ethics of Clinical Research from the Ethics of Medical Care, 33 J.L. MED. & ETHICS 566, 570 
(2005) (“[U]nder the seven principles for research, it would be unethical to withhold effective 
treatment to such ill persons for research purposes if withholding treatment exposes a person to 
grave risk.”).  For the same reason, once data establishes efficacy and safety during a trial to 
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given the standard treatment alone or, where there are multiple treatment 
options, the drug candidate with varied couplings.73 
Since the introduction of the Prescription Drug User Fee Act in 1992 
(“PDUFA”), the FDA has been granting accelerated approval of novel drugs 
based upon surrogate endpoints—laboratory measures that suggest 
improvements in patient health rather than factual documentation of actual 
impact given a contained timeframe—in accordance with formal clinical 
standards, meaning patient health improvements.74  Inferences about the drug 
candidates are based on statistical comparisons of group mean scores.75  The 
ultimate compilation is a statistical common denominator across the full target 
disease population. 
A major limitation in GD for drug development is that human variability 
among study participants may prove significantly more substantial than 
anticipated even though, symptomatically, the subjects appear to share what 
has been classified a disease.76  The mathematical abstract derived from the 
population may predict nothing for any individual participant.  As explained by 
Professor Janosky, 
[P]atients are unique and may not respond similarly to various treatments, and 
in those instances a randomized clinical trial design may be inappropriate.  
 
develop treatments for such conditions, study sponsors typically must make the drug candidate 
available to all of those in its trials.  Id. 
 73. See supra note 72 and accompanying text. 
 74. 21 C.F.R. § 314.510 (2010).  The ICH E9 Guidance suggests that, 
In choosing which clinical endpoints to test for, the guidance recommends that sponsors 
select primary endpoints capable of providing the most clinically relevant and convincing 
evidence directly related to the trial’s main objective. Typically, there should be but one 
primary endpoint. Usually, efficacy should be the primary endpoint, although safety, 
tolerability, or quality-of-life measurements also may serve as the foremost endpoints to 
be tested, the guidance states. 
ICH Guidance Examines, supra note 28.  The FDA has been criticized for accepting surrogate 
endpoints for accelerated, conditional market approval and then failing to enforce follow-on study 
requirements.  U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-09-866, NEW DRUG APPROVAL: 
FDA NEEDS TO ENHANCE ITS OVERSIGHT OF DRUGS APPROVED ON THE BASIS OF SURROGATE 
ENDPOINTS 29 (2009).  According to the GAO, the FDA has required over 144 studies since 
introducing the accelerated approval program in 1992.  Id. at 18.  More than a third of those are 
still pending and the Agency never has pulled a drug for failure to conduct long-term studies.  Id. 
at 18, 29.  The FDA does not routinely check whether companies are making progress on required 
studies.  Id. at 29–32. 
 75. See supra notes 10, 17 and accompanying text (explaining the use of averages in GD 
statistics). 
 76. This point is illustrated in a discussion of the tremendous genetic diversity associated 
with the health care condition categorized as “dwarfism.”  See Michael J. Malinowski, Dealing 
with the Realities of Race and Ethnicity: A Bioethics-Centered Argument in Favor of Race-Based 
Genetics Research, 45 HOUS. L. REV. 1415, 1451–57 (2009) (profiling the Roloff family from the 
television show “Little People, Big World” as a case study). 
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Guidelines are established from the averaged study findings, which may not 
necessarily be applicable when evaluating suitable treatment options for 
individuals.  Specifically, patients treated in primary care settings may differ 
clinically from patients in the clinical trial, the patient diversity in the clinical 
trial may not generalize to certain patient populations, and the stringent trial 
criteria for accepting participants may not accurately reflect general patient 
populations.77 
The effort to account for human variability and to generate a meaningful 
predictor of drug performance through GD, to the extent that is possible, 
demands thousands of participants at multiple locations—a need that has 
increased substantially over the last decade and pushed drug sponsors to 
outsource both toxicology studies and human clinical trials to contract research 
organizations (“CRO”).78  “In the past, a single phase three trial might have 
needed 3,000 patients and cost between $10 million and $20 million.  Today, 
the same kind of study would take 20,000 patients and cost $50 million to $100 
million . . . .”79  While the trend is expansion of clinical trial recruitment 
outside of the U.S. borders,80 “[t]he number of clinical trials in the United 
States has climbed dramatically in recent years.  Between 2000 and 2006, 
 
 77. JANOSKY ET AL., supra note 6, at 81–82 (footnotes omitted).  The renowned Dr. Jerome 
Groopman has reached the same conclusion: “Statistics cannot substitute for the human being 
before you; statistics embody averages, not individuals.  Numbers can only complement a 
physician’s personal experience with a drug or a procedure, as well as his knowledge of whether a 
‘best’ therapy from a clinical trial fits a patient’s particular needs and values.”  JEROME 
GROOPMAN, HOW DOCTORS THINK 6 (2007).  Similarly, as observed by another commentator: 
  The best way to go from intuition to evidence is the randomized clinical trial.  
Patients with a particular condition are randomly assigned to competing treatments or, if 
appropriate, to a placebo.  By monitoring the patients for months or years, doctors learn 
the relative risks and benefits of the treatment being studied. 
  But such trials take years and cost many millions of dollars.  By the time the results 
come in, science and medicine may have moved on, making the findings less relevant.  
Moreover, patients in a clinical trial usually aren’t representative of real people, who 
tend to have complex combinations of diseases and medical problems.  And patients often 
don’t stick with the program. 
Carey, supra note 6, at 77 (emphasis added). 
 78. Nagano, supra note 1. 
 79. Id. 
 80. Id.  In addition to the speed of subject recruitment (the primary driver for expansion of 
recruitment outside of the United States), 
To seek bigger patient pools, most major CROs have expanded operations overseas to 
India, Russia, Latin America, Eastern Europe and other emerging markets.  U.S.-based 
CROs have a presence in more than 70 countries. 
  In those countries, CROs can easily find a large number of “treatment-naïve 
patients” who aren’t taking other drugs and are thus the best candidates for trials. 
Id. 
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clinical trials increased from 40,000 to 59,000—a nearly 50 percent jump.”81  
Though industry is spending unprecedented amounts on clinical research and 
conducting more and larger clinical trials, the sobering outcome is a steep drop 
in innovative new drug approvals in recent years.82 
Congress has recognized and responded to the drug development dilemma 
by forcing more of GD through the FDAAA and culling more data around it 
rather than questioning the methodology.83  The current administration is 
concerned enough to introduce a billion-dollar center, funded in a time of 
economic trouble, to infuse government-performed research assistance in order 
to help industry put more new drugs on pharmacy shelves.84 
B. The Advent and Evolution of SSRD 
SSRD is a natural science research methodology developed in practice and 
addressed in literature for over a half a century in disciplines such as behavior 
analysis, education, physical therapy, and occupational therapy.85  “Although 
there is a long tradition of employing single subject designs in social science 
research, these designs have only recently been utilized in biomedicine,”86 and 
“these methods have been used infrequently in clinical 
psychopharmacology.”87  However, the cross-discipline popularity of SSRD is 
on the rise: “In recent literature, it appears these designs are receiving more 
recognition, as they are being increasingly employed in research across 
disciplines.”88 
The core SSRD methodology is to repeat comparisons of control and 
treatment conditions with the same individual or staggered across similar 
individuals, graph the data on a subject-by-subject basis, and then analyze the 
resulting data.89 
 
 81. CTR. FOR HEALTH & PHARM. LAW & POLICY, SETON HALL LAW, WHITE PAPER: 
CONFLICTS OF INTEREST IN CLINICAL TRIAL RECRUITMENT & ENROLLMENT: A CALL FOR 
INCREASED OVERSIGHT 5 (2009). 
 82. See infra Part II. 
 83. See supra notes 23–25 and accompanying text. 
 84. Gardiner Harris, A New Federal Research Center Will Help to Develop Medicines, N.Y. 
TIMES, Jan. 23, 2011, at A1. 
 85. See supra note 7 and accompanying text.  For detailed discussion of the SSRD 
methodology, see JANOSKY ET AL., supra note 6, at 25–43. 
 86. JANOSKY ET AL., supra note 6, at 81; see also id. at 81–96 (discussing direct application 
of SSRD in biomedicine). 
 87. Poling et al., supra note 3, at 119. 
 88. JANOSKY ET AL., supra note 6, at 82. 
 89. Green, supra note 6, at 74.  “In a single-case experiment, each data point represents one 
of the repeated direct measurements of the target behavior, as opposed to a mathematical abstract 
like a group mean test score.  Graphing those data provides a picture of exactly how behavior 
unfolds in real time under specific conditions.”  Id. at 78. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
384 SAINT LOUIS UNIVERSITY LAW JOURNAL [Vol. 56:363 
Single-case design experiments to evaluate treatment effects involve directly 
observing and measuring one or more specific behaviors of an individual 
repeatedly for a period of time while a particular treatment is not in place (the 
control or baseline condition), and while it is (the experimental or treatment 
condition). . . . Comparisons of control and treatment conditions are repeated, 
or replicated, with the same individual and/or with other similar individuals.90 
Human variability is accounted for in single subject research by 
manipulating environmental variables that occasion steady states of 
responding—rather using statistical analysis to herd subjects into what are 
declared to be steady states for the individual, but actually represent only group 
averages.  Specifically, 
In applied single-case studies, the interest is not in statistically significant 
differences between group mean scores but in clinically and educationally 
important improvements in individual behavior in comparison to baseline.  In 
many behavior analytic studies, those changes—that is, differences in data 
from the control and treatment conditions—far exceed what is required for 
statistical significance.  Individual differences in responses to treatment and 
variability in behavior are not viewed as “noise” to be wiped out 
mathematically, but as natural features of behavior to be studied further so they 
can be better understood.  Replication, which is an essential ingredient of 
science, is built into single-case designs. . . . The evidence for those 
conclusions comes from conditions where the treatment and other variables are 
tightly controlled and the effects of the treatment on behavior are observed 
directly, rather than from statistical transformations of numbers that do not 
represent actual behavior.91 
The SSRD and GD methodologies for responding to variability in 
outcomes are fundamentally different.92  In GD, researchers typically use large 
samples to average out differences in outcomes, while SSRD researchers 
attempt to bring outcome differences under experimental control—in other 
words, statistical control over error through large samples under GD, versus 
experimental control to reduce error with a heightened focus on individual 
subject responses under SSRD.93  As pointed out by Professor Janosky, 
[The GD] strategy is problematic for two reasons: (1) statistical power and 
sample size are related, with larger samples at times leading to significant but 
very small effects with little pragmatic value and (2) it discourages the 
researcher from strategically modifying treatment (i.e., response guided 
experimentation) that may positively impact most if not all the patients.94 
 
 90. Id. at 74.  For an overview on SSRD methodology, see Blampied Presentation, supra 
note 7. 
 91. Green, supra note 6, at 78–79. 
 92. JANOSKY ET AL., supra note 6, at 28. 
 93. Id. 
 94. Id. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2012] DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY? 385 
In contrast, under SSRD, patient responsiveness is probed through 
modification of, and changes in, the treatment as a consequence of response-
guided experimentation.95 
Ultimately, the objective driving drug development must be the 
improvement of patient health.  The medical community effectively engages in 
a simulation of SSRD through often creative patient-by-patient treatment with 
biopharmaceuticals under its discretion to use them off-label—a “cart before 
the horse approach” so to speak.  In the words of some thoughtful observers, 
“[t]o some extent, clinical medicine always has been tailored to the patient in 
that each physician-patient relationship is unique, and each clinical encounter 
represents the physician’s attempt to provide the optimal care to the patient in 
the examining room, the emergency room, the hospital bed, and the intensive 
care unit.”96 
SSRD’s focus on the individual has made the methodology a natural fit for 
the field of behavior analysis.97  In fact, much of the groundwork is attributable 
to B.F. Skinner and dates back to the 1930s: 
Skinner emphasized studying the individual to determine lawful models of 
behavior.  He drew heavily upon animal research, often using pigeons or rats, 
to uncover fundamental learning principles that could then be applied to 
humans.  Inevitably, similar procedures for modifying behavior were applied 
to individual human subjects.  Within the realm of applied behavior analysis, 
single subject design studies began examining methods for modifying behavior 
of individuals with diverse psychological problems, including stuttering, 
learning disabilities, mental retardation, and psychotic symptoms.98 
SSRD has had a profound impact in the treatment of individuals with 
autism spectrum disorder and other severe learning disabilities.99  For example, 
the CABAS® model, a comprehensive approach to behavior analysis and 
schooling,100 has yielded an abundance of procedures, tactics, interventions, 
and large scale protocols for parents, educators, and children with a wide 
 
 95. Id. 
 96. Patient-Tailored Medicine Part One, supra note 13, at 9. 
 97. See Green, supra note 6, at 73.  As explained by Professor Green, “[l]ike other scientists, 
behavior analysts have devised research methods that are suited to their particular subject matter, 
while meeting all of the general requirements of science.”  Id. at 73.  These requirements include 
careful observation, objective measurement, controlled experiments, analysis and interpretation of 
data, and repetition (replication) of experiments.  Id. at 70.  Because the focus is on individual 
behavior unfolding over time, single-case research designs are used for most behavior analytic 
studies.  These are true experiments, not “case studies” or nonexperimental observational studies.  
Id. at 74. 
 98. JANOSKY ET AL., supra note 6, at 28 (citations omitted).  R.A. Fisher introduced the first 
official single subject clinical trial experimental paradigm in 1945.  Id. at 1. 
 99. See supra note 33 and accompanying text. 
 100. See supra note 33 and accompanying text. 
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variety of disabling conditions.101  The underlying theme of all CABAS® 
research is adhering to scientific rigor based on John Stuart Mill’s five canons 
of the scientific method.102  Through tightly controlled scientific studies 
conducted by practitioners, CABAS® research has promoted the growth and 
development of academic social repertoires for children, and generally enabled 
learning and function in thousands of children deemed “unteachable.”103  
While education is a field susceptible to trends, untestable theories, and heavy 
reliance on construct attributes, SSRD has allowed the field of behavior 
analysis to establish grounded, effective approaches and documented success 
with severely learning-disabled children through natural science evaluation in 
human clinical research.  Interestingly, while SSRD methods have been 
developed through and used significantly in ABA, they have been used 
infrequently in clinical psychopharmacology.104 
II.  DRUG UNDERDEVELOPMENT 
Throughout much of the twentieth century and into the present one, 
pharmaceutical research and development (“R&D”) has been the most 
profitable sector.105  For decades, our tendency as patients and consumers has 
been to believe that prescription medications improve human health and, in 
turn, to associate medicine closely with science—especially when grappling 
with a seriously debilitating illness.106  There have been profound 
improvements to human health through pharmaceuticals for well over a half 
century,107 but the overall reality is that the prescription medication arsenal to 
treat all human ailments prior to the 1990s consisted of merely 2000–3000 
commercial pharmaceuticals derived from 483 drug targets (compounds that 
serve as the basis for medicinal applications).108 
 
 101. See Greer & Keohane, Real Science, supra note 30, at 37–38. 
 102. See R. DOUGLAS GREER, DESIGNING TEACHING STRATEGIES: AN APPLIED BEHAVIOR 
ANALYSIS APPROACH 161–163 (2002). 
 103. Joe Levine, The Unorthodox Behaviorist, TC TODAY, Spring 2007, at 24, 26–27. 
 104. Poling et al., supra note 3, at 119. 
 105. MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES, at xv (2004). 
 106. See PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE, 336–37 
(1982) (detailing a growing dependence on pharmaceuticals and medical technology following 
World War I). 
 107. See, e.g., id. at 335–36 (noting, for example, advances in antibiotics and Malaria 
control). 
 108. Jürgen Drews, Drug Discovery: A Historical Perspective, 287 SCI. 1960, 1962 (2000); 
Michael J. Malinowski, Respecting, Rather than Reacting to, Race in Basic Biomedical Research: 
A Response to Professors Caulfield and Mwaria, 45 HOUS. L. REV. 1489, 1492 n.16 (2009); 
Thomas Reiss, Drug Discovery of the Future: The Implications of the Human Genome Project, 
19 TRENDS BIOTECHNOLOGY 496, 496 (2001).  “This surprisingly low number of targets 
illustrates that the identification of clinically relevant and interesting targets was the primary 
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A. The Twentieth Century Drug Development Experience 
The crudeness of the underlying science relied upon is self-evident in the 
twentieth century drug development experience.  Historically, developers 
would sort through thousands of drug targets to produce just one 
pharmaceutical success.109  The endeavor focused on taking away the 
symptoms of disease—not on understanding and treating the causes of 
disease.110  “[D]rug discovery essentially was a linear process based upon 
screening and testing of thousands of chemicals and natural substances for 
potential therapeutic activity.  Screening was time consuming and largely 
random because drug targets and drug functions were in most cases 
unknown.”111  Compounds were introduced in living organisms to identify 
their effect and potential medicinal utilities, purified to control toxicity in 
conjunction with at least one medicinal use, and introduced onto the market 
with the expectation that physicians would experiment further while practicing 
medicine on patients and identify additional clinical utilities through off-label 
uses.112 
Drug sponsors were not even required to demonstrate efficacy for market 
access until 1962.113  The regulatory standard for market approval of a drug 
candidate in the United States has been eliminating symptoms, even if just 
marginally more effectively than a placebo, coupled with a showing that 
adverse events and other safety issues across the target disease population are 
tolerable given the benefits.114  This standard, paired with the discretion of 
 
bottleneck of the drug discovery process.”  Patient-Tailored Medicine Part One, supra note 13, at 
12. 
 109. Drug Discovery and Development, PHRMA, http://www.Phrma.org/research/drug-
discovery-development (last visited Dec. 29, 2011). 
 110. See Evans, Seven Pillars, supra note 24, at 439–44 (discussing efficacy as the purpose of 
randomized, controlled clinical trials). 
 111. Patient-Tailored Medicine Part One, supra note 13, at 11–12 (citing Press Release, Tufts 
Ctr. for the Study of Drug Dev., Backgrounder: How New Drugs Move Through the 
Development and Approval Process (Nov. 2001), available at http://csdd.tufts.edu/files/uploads/ 
how_new_drugs_move.pdf); see generally Jim Gilbert et al., Rebuilding Big Pharma’s Business 
Model, IN VIVO: BUS. & MED. REP., Nov. 2003, at 73 (2003), available at www.bain.com/bain 
web/PDFs/cms/Marketing/rebuilding_big_pharma.pdf (outlining the traditional methods that 
have led the drug industry to profit loss, including a random, all-inclusive, expensive testing 
process). 
 112. See supra notes 19–22 and accompanying text. 
 113. Thomas, supra note 58, at 372; Patient-Tailored Medicine Part One, supra note 13, at 
24; Harris Meyer, Costly Stamp of Approval, L.A. TIMES, Jan. 18, 2010, at E3.  Sponsors have 
been required to demonstrate safety since 1938.  Id. 
 114. Patient-Tailored Medicine Part One, supra note 13, at 9 (“Nonetheless, not until the 
second half of the twentieth century has much attention been paid to drug safety and, even then, 
adverse drug reactions were considered part of the practice of medicine.”); David Classen, 
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commercial sponsors to tailor clinical research and to apply (or not) for 
approval of specific uses in applications for market access, has invited 
tremendous off-label use by the U.S. medical profession once products reach 
the market.115  Though the biopharmaceutical sectors spend tens of billions of 
dollars on research annually,116 they spend more on marketing—both legal and 
illegal.117  Much of their marketing is directed at encouraging the medical 
community to exercise its discretion to use their products off-label.118  Off-
label use is motivated further by publication of industry-sponsored research in 
science and medical journals, direct-to-consumer marketing,119 and patient 
faith in new treatments, including experimental ones.120  Even when marketed 
legally, only “[o]ne-third of all drugs act as expected when prescribed to 
patients,” and there are approximately two million adverse drug reactions 
requiring hospitalization each year.121  Adverse drug reactions cause more than 
 
Medication Safety: Moving from Illusion to Reality, 289 JAMA 1154, 1154 (2003); Evans, Seven 
Pillars, supra note 24, at 449. 
 115. See Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 350 (2001); Wash. Legal 
Found. v. Henney, 202 F.3d 331, 333 (D.C. Cir. 2000) (calling off-label use “commonplace”); 
Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998), vacated in part on other 
grounds sub nom. Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000) (observing that 
“off-label use of FDA-approved drugs by physicians is an established aspect of the modern 
practice of medicine”). 
 116. PHARM. RESEARCHERS & MFRS. OF AM., PHARMACEUTICAL INDUSTRY PROFILE 26 
fig.8 (2010); see CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81, at 9 (calling the 
cost of “nontreatment activities,” including research, considerable and substantial). 
 117. ANGELL, supra note 105, at 11–12.  The FDA has estimated that almost two percent of 
all prescription drugs—thousands of medicines that include powerful active ingredients such as 
antihistamines, narcotics and sedatives—are marketed illegally without its approval.  Meyer, 
supra note 113. 
 118. Meyer, supra note 113 (explaining that high prices of FDA-approved drugs leads to use 
of cheaper, unapproved off-label drugs). 
 119. ANGELL, supra note 105, at 123–26 (describing how direct-to-consumer advertising both 
persuades and misleads consumers). 
 120. See INST. OF MED., supra note 67, at 2 (suggesting black triangle indicators for new drug 
approvals to flag the lack of market history); Wylie Burke & Bruce M. Psaty, Personalized 
Medicine in the Era of Genomics, 298 JAMA 1682, 1682–84 (2007) (detailing the potential of 
experimental, genetically personalized pharmaceutical treatment). 
 121. Patient-Tailored Medicine Part One, supra note 13, at 9, 16–17; see also INST. OF MED., 
THE FUTURE OF DRUG SAFETY: PROMOTING AND PROTECTING THE HEALTH OF THE PUBLIC 54 
box2-5 (2007) (relating drug-specific data on adverse effects as reported to the FDA). 
To some extent, clinical medicine always has been tailored to the patient in that each 
physician-patient relationship is unique, and each clinical encounter represents the 
physician’s attempt to provide the optimal care to the patient in the examining room, the 
emergency room, the hospital bed, and the intensive care unit.  Nonetheless, not until the 
second half of the twentieth century has much attention been paid to drug safety and, even 
then, adverse drug reactions were considered part of the practice of medicine. 
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100,000 deaths annually in the U.S.—meaning that more people in the U.S. die 
from legal use of prescription medications than from automobile accidents.122  
Medicine remains much more art than science: 
Even today, with a high-tech health-care system that costs the nation $2 trillion 
a year, there is little or no evidence that many widely used treatments and 
procedures actually work better than various cheaper alternatives. 
  . . . . 
  . . . And while there has been progress in recent years, most of these 
physicians say the portion of medicine that has been proven effective is still 
outrageously low—in the range of 20% to 25%.123 
B. Today’s Drug Research and Development Potential 
Drug development has changed fundamentally.124  The legacies of 
discretion to commercial sponsors over the content of clinical research and to 
the medical community over off-label use are prevalent today, but the science 
of drug development has evolved and is undergoing a genomics (genetic 
expression) metamorphosis—a “genomics revolution.”125  The prevalence of 
“biopharmaceuticals” in the drug development pipeline and the centralized 
review of all new drugs, whether based primarily in biology or chemistry, 
within the Center for Drug Evaluation and Research (CDER) beginning in 
2004126 confirm that pharmaceutical R&D and biotech have integrated 
extensively.127 
 
  Today, because adverse drug reactions cause more than two million hospitalizations 
and 100,000 deaths annually in the United States, there are strong clinical, economic, and 
ethical imperatives to address the manifold causes of these numbers. 
Patient-Tailored Medicine Part One, supra note 13, at 9 (footnotes omitted).  See also BS 
Shastry, Pharmacogenetics and the Concept of Individualized Medicine, 6 PHARMACOGENOMICS 
J. 16, 16 (2006).  Negative outcomes may result both from errors in prescribing and dispensing 
and from individuals’ adverse reactions to the drugs themselves.  Petra A. Thürmann, Prescribing 
Errors Resulting in Adverse Drug Events: How Can They Be Prevented?, 5 EXPERT OPINION ON 
DRUG SAFETY 489, 490 (2006).  It is entirely possible that one of the causes of adverse drug 
reactions is the method by which individual patients metabolize those drugs.  Kathryn A. Phillips 
et al., Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic 
Review, 286 JAMA 2270, 2270 (2001). 
 122. Shastry, supra note 121, at 16.  One 2005 report stated that approximately 40,000 people 
are killed in automobile accidents every year.  Miranda Hitti, Car Crashes Kill 40,000 in U.S. 
Every Year, FOX NEWS (Feb. 3, 2005), http://www.foxnews.com/story/0,2933,146212,00.html. 
 123. Carey, supra note 6, at 73 (reporting on the movement for evidence-based medicine). 
 124. See generally STARR, supra note 106. 
 125. See generally Genomics Revolution, supra note 13; Nagano, supra note 1 (“The 
consensus on Wall Street: Big Pharma’s business model is ‘broken, and no longer 
working’ . . . .”). 
 126. See Press Release, U.S. Food & Drug Admin., FDA Completes Final Phase of Planning 
for Consolidation of Certain Products from CBER to CDER, (Mar. 17, 2003), available at 
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The potential of ongoing drug development, with a map of the human 
genome in hand128 and the creation of more profound tools underway,129 
arguably is limited only by human ingenuity given increasing abilities to 
manipulate the “highly sophisticated, delicate regulatory pathways and 
 
http://www.scienceblog.com/community/older/archives/M/2/fda1387.htm.  Until 2004, biologic 
drugs were reviewed by the Center for Biologics Evaluation and Research.  Transfer of 
Therapeutic Products to the Center for Drug Evaluation and Research, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ 
CBER/ucm133463.htm (last visited Dec. 29, 2011).  Where the drugs were a combination of 
traditional and biotech, sponsors had some choice in where to file for review.  Influenced by the 
trend of biopharmaceuticals, all drug review and the relevant resources were centralized in 
CDER.  Id. 
 127. See Transfer of Therapeutic Products, supra note 126. 
 128. See Press Release, Nat’l Human Genome Research Inst., International Consortium 
Completes Human Genome Project, (Apr. 14, 2003), available at http://www.genome.gov/ 
11006929 [hereinafter International Consortium].  The Human Genome Project (“HGP”), 
commenced in 1990, was undertaken to identify and map the sequence of information coded in 
DNA and to identify active human genes—segments of DNA.  Id.; Patient-Tailored Medicine 
Part One, supra note 13, at 10–11.  A rough map of the human genome was completed in 2003, 
years ahead of schedule.  Patient-Tailored Medicine Part One, supra note 13, at 11.  Information 
about the HGP may be obtained from the National Human Genome Research Institute 
(“NHGRI”) at www.nhgri.nih.gov/HGP.  For more information on the human genome generally, 
see the February 16, 2001 issue of Science entitled “The Human Genome,” 291 SCI. 1145 (2001) 
and the February 15, 2001 Issue of Nature, 409 NATURE 745 (2001), also entitled “The Human 
Genome” dedicated to a draft of the map of the human genome.  See also SUBCOMM. ON HUMAN 
GENOME OF THE HEALTH & ENVTL. RESEARCH ADVISORY COMM. FOR THE U.S. DEP’T OF 
ENERGY, REPORT ON THE HUMAN GENOME INITIATIVE FOR THE OFFICE OF ENVIRONMENTAL 
RESEARCH (1987), available at www.ornl.gov/sci/techresources/Human_Genome/project/herac 
2.shtml (discussing the need for and value of a map of human DNA); Eric S. Lander, Scientific 
Commentary: The Scientific Foundations and Medical and Social Prospects of the Human 
Genome Project, 26 J.L. MED. & ETHICS 184, 184 (1998) (explaining the HGP and the 
possibilities that arise with unlocking the “human periodic table”).  Once genes are identified, 
comparisons can be made among individuals to identify genetic variations and assess their 
function and impact on human health.  See CTR. FOR GENETICS EDUC., THE HUMAN GENETIC 
CODE—THE HUMAN GENOME PROJECT AND BEYOND (2007), available at www.genet 
ics.com.au/pdf/factsheets/fs24.pdf (noting diagnosis and predictive testing for genetic conditions). 
 129. See Press Release, Nat’l Human Genome Research Inst., International Consortium 
Announces the 1000 Genomes Project (Jan. 22, 2008), available at http://www.1000ge 
nomes.org/sites/1000genomes.org/files/docs/1000genomes-newsrelease.pdf. 
An international research consortium today announced the 1000 Genomes Project, an 
ambitious effort that will involve sequencing the genomes of at least a thousand people 
from around the world to create the most detailed and medically useful picture to date of 
human genetic variation.  The project will receive major support from the Wellcome Trust 
Sanger Institute in Hinxton, England, the Beijing Genomics Institute, Shenzhen (BGI 
Shenzhen) in China and the National Human Genome Research Institute (NHGRI), part 
of the National Institutes of Health (NIH). 
Id. 
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feedback loops”130 of drug targets through the precision of genetics and 
identification of environmental influences.131  Today holds the promise of 
infiltrating disease pathways on the cellular, genetic, and molecular levels to 
treat the causes of disease and thereby improve human health well beyond 
existing capabilities.132 
The completion of the human genome map in 2003 made it possible to identify 
an individual’s genetic makeup to determine disease risk, and a patient’s likely 
response to certain medications.  Genetic information may be used to diagnose 
a condition in an individual prenatally or prior to the presentation of any 
clinical symptoms.133 
Millions of associations have been made between genetic variations and 
human health, and each constitutes a potential drug target.134  Increasingly, 
discussion of a forthcoming era of personalized medicine—engineering 
medications tailored to individual patient’s genetic makeup (pharmacogenetics, 
developed through pharmacogenomics)135—and extensive genetic profiling as 
part of both preventive care and treatment carries a tone of “when” rather than 
“if.”136  Overall, there is considerable consensus that “the availability of the 
 
 130. Peter Imming et al., Drugs, Their Targets and the Nature and Number of Drug Targets, 
5 NATURE REVIEWS: DRUG DISCOVERY 821, 830 (2006).  A drug target is “a molecular structure 
(chemically definable by at least a molecular mass) that will undergo a specific interaction with 
chemicals that we call drugs because they are administered to treat or diagnose a disease. The 
interaction has a connection with the clinical effect(s).”  Id. at 821. 
 131. See supra note 13 for a discussion of epigenetics. 
 132. See BIOTECHNOLOGY INDUS. ORG., GUIDE TO BIOTECHNOLOGY 2008 32–40 (2008), 
available at http://www.bio.org/node/2801 (discussing some of the therapies made possible by 
recent research advances). 
 133. Patient-Tailored Medicine Part One, supra note 13, at 11. 
 134. William E. Evans & Mary V. Relling, Moving Towards Individualized Medicine With 
Pharmacogenics, 429 NATURE 464, 466, 468 (2004).  More than 3 million human genetic 
variations, called single nucleotide polymorphisms (“SNPS”), had been identified by April 2003.  
International Consortium, supra note 128. 
 135. In simplest terms, pharmacogenomics utilizes genetic profiling in pharmacology—for 
example, centering a human clinical trial on members of a disease group under study who share a 
particular genetic variation.  When successful, the result is associations between specific human 
genetic variations and responsiveness to pharmaceuticals, thereby enabling individualized 
medicine based on genetic profiling, which is a field known as pharmacogenetics.  See supra 
notes 46–47 and accompanying text.  Complementary fields are pharmacogenomics, which is 
research centered on the expression of alleles shared by groups, and pharmacogenetics, the 
tailoring of health care and biopharmaceuticals to individual genetic profiles.  See Malinowski, 
supra note 13, at 32; Noah, supra note 13, 7–11; Janet Woodcock, FDA Policy on 
Pharmacogenomic Data in Drug Development, 66 LA. L. REV. 91, 92 (2005). 
 136. See Patient-Tailored Medicine Part One, supra note 13, at 6–7; Burke & Psaty, supra 
note 120, at 1684; Susan B. Shurin & Elizabeth G. Nabel, Pharmacogenomics—Ready for Prime 
Time?, 358 NEW ENG. J. MED. 1061, 1062–63 (2008).  “Biotechnology also has created a wave of 
new genetic tests.  Today there are more than 1,200 such tests in clinical use, according to 
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human genome sequence, together with the pharmacogenomic and 
pharmacogenetic approaches to developing new drug therapies, has and will 
continue to contribute to a better selection and faster development of safer and 
more effective diagnostics and treatments.”137  Affirmations of the health care 
potential of contemporary biopharmaceutical R&D include Herceptin,138 
Gleevec,139 and Olaparib.140 
C. Drug Disappointments and Desperation 
Unfortunately, the present reality is that drug development lingers between 
the scientifically crude, yet enormously profitable pharmaceutical past and the 
biopharmaceutical present and future.141  “Ten years after President Bill 
Clinton announced that the first draft of the human genome was complete, 
medicine has yet to see any large part of the promised benefits.”142  The 
transition could take many years—decades according to some 
commentators.143  In recent years, drug development disappointments have 
vastly outnumbered successes in spite of tremendous investment.144  According 
to the pharmaceutical industry’s trade organization, the Pharmaceutical 
Research and Manufacturers of America (“PhRMA”), “In 2009, America’s 
pharmaceutical research and biotechnology companies continued to make the 
 
genetests.org, a site sponsored by the University of Washington.  Many are for genetic diseases, 
while others test predisposition to disease.  Emerging applications include tests to predict 
response to medicines and assist with nutritional planning.”  BIOTECHNOLOGY INDUS. ORG., 
supra note 132, at 32. 
 137. Patient-Tailored Medicine Part One, supra note 13, at 12.  See also The Int’l SNP Map 
Working Grp., A Map of Human Genome Sequence Variation Containing 1.42 Million Single 
Nucleotide Polymorphisms, 409 NATURE 928, 932 (2001) (discussing the various benefits 
anticipated from the human genome map). 
 138. See generally ROBERT BAZELL, HER-2: THE MAKING OF HERCEPTIN, A 
REVOLUTIONARY TREATMENT FOR BREAST CANCER (1998). 
 139. Brian J. Druker, STI571 (GleevecTM) as a Paradigm for Cancer Therapy, 8 TRENDS 
MOLECULAR MED. S14, S14 (2002). 
 140. Steven Reinberg, New Cancer Drug Fights Tumors in Those with BRCA Mutations, U.S. 
NEWS & WORLD REP. (June 24, 2009), http://health.usnews.com/articles/health/healthday/2009/ 
06/24/new-cancer-drug-fights-tumors-in-those-with-brca.html. 
 141. See ANGELL, supra note 105, at xv–xvii; U.S. FOOD & DRUG ADMIN., INNOVATION OR 
STAGNATION: CHALLENGE AND OPPORTUNITY ON THE CRITICAL PATH TO NEW MEDICAL 
PRODUCTS (2004), available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ 
CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf (providing a 
comprehensive discussion on the challenges facing biopharmaceuticals, despite recent advances 
in biomedical research, as well as potential solutions); Bitter Medicine: Pills, Profit, and the 
Public Health (ABC News television broadcast May 29, 2002). 
 142. Nicholas Wade, A Decade Later, Gene Map Yields Few New Cures, N.Y. TIMES, June 
13, 2010, at A1. 
 143. See Patient-Tailored Medicine Part One, supra note 13, at 35. 
 144. See supra notes 1–3 and accompanying text. 
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world’s largest investment in pharmaceutical R&D, holding steady with $65.3 
billion spent on R&D, including $45.8 billion by PhRMA members alone.”145  
Nevertheless, new drug approvals fell to a twenty-five year low in 2007, just 
eighteen, followed by a slight bump to twenty-four in 2008 and twenty-six in 
2009.146  In 2010, Pfizer Inc., the world’s largest research-based 
pharmaceutical company, did not produce a single new drug approval.147  In 
comparison, new drug approvals peaked in 1996 when the FDA approved 
fifty-three.148  According to Dr. Francis Collins, Director of the National 
Institutes of Health, this decline in productivity over the past fifteen years 
“certainly doesn’t show any signs of turning upward.”149  In fact, the federal 
government has become concerned enough about the performance of the 
commercial biopharmaceutical sectors to start a “billion-dollar government 
drug development center to help create new medicines.”150  Industry continues 
to spend enormous amounts of money to make new drugs.151 
The drop in new drug approvals has taken place in spite of annual 
governmental investments of billions of dollars in biomedical research and a 
substantial increase in commercial investment in biopharmaceutical R&D.  
“Before 1980, the National Institutes of Health (NIH) funded most medical 
research. . . . Today, drug and medical device companies fund up to 80% to 
90% of all clinical trials; in 2005, industry invested 78% more in research and 
development than did the federal government.”152  Though the trend is to 
export clinical research beyond the U.S. borders and to outsource it to 
CROs,153 the amount of clinical research undertaken today within the United 
States is unprecedented—an almost fifty percent increase during the first half 
of this decade.154  Phase III trials have expanded to 20,000 subjects from just 
 
 145. PHARM. RESEARCHERS & MFRS. OF AM., supra note 116, at iii. 
 146. Jared A. Favole & Jennifer Corbett Dooren, FDA Approved More Drugs in 2008, WALL 
ST. J., Jan. 2, 2009, at A9; New Drug Approvals on Pace to Exceed 2008 Total, supra note 1; 
Silverman, supra note 1; see also Jenna Greene, Has Obama Redirected the Regulatory System?, 
NAT’L L. J., Jan. 18, 2010, at 11 (noting that the number of FDA approvals under the Obama 
administration are “on par or even more accommodating than” the Bush Administration); Pete 
Harpum, Articulating a Vision for Best Practice Project Management in Drug Development, PM 
WORLD TODAY, Oct. 2008, at 1, http://www.pmforum.org/library/papers/2008/PDFs/Harpum-10-
08.pdf. 
 147. See Asher Mullard, 2010 FDA Drug Approvals, 10 NATURE REVS.: DRUG DISCOVERY 
82, 84 tbl.1 (2011) (listing CDER’s approvals in 2010 in chart form). 
 148. FDA’s Drug Approvals Flat 2009, Safety Up, MSNBC (Jan. 5, 2010, 1:37 PM), 
http://www.msnbc.msn.com/id/34708085/ns/health-health_care/t/fdas-drug-approvals-flat-safety/. 
 149. Harris, supra note 2. 
 150. Id. 
 151. Id. 
 152. CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81, at 6. 
 153. Nagano, supra note 1. 
 154. CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81, at 5. 
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3,000 five years ago, which has doubled their cost—now typically $50–100 
million.155 
In addition to the decline in new drug approvals, many of the prescription 
drugs the FDA has put on the market in recent years have proven 
disappointing.  There is ample reason to question their quality and the 
Agency’s performance overseeing them.156  Most notably, Vioxx has become a 
“scarlet letter” the FDA is likely to wear for years to come,157 and many 
additional prescription drug problems have followed in recent years.  In the fall 
of 2010, the FDA itself “concluded that in some cases two types of drugs that 
were supposed to be preventing serious medical problems were, in fact, 
causing them.”158  These were Avandia, prescribed heavily to treat type-2 
diabetes, and bisphosphonates—an active agent in the prescription drugs 
Fosamax, Actonel, and Boniva—used widely to prevent fractures common in 
people with osteoporosis.159  Avandia was associated with an increased risk of 
heart attacks and strokes, a major problem for its target patient group given 
two thirds of diabetics die of heart problems,160 and bisphosphonates was 
 
 155. Nagano, supra note 1. 
 156. See U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67; INST. OF MED., supra note 67. 
 157. Thomas, supra note 58, at 371–73. 
 158. Gina Kolata, When Drugs Cause Problems They Are Supposed to Prevent, N.Y. TIMES, 
Oct. 17, 2010, at A18. 
 159. Id. 
 160. Id.  The recent Avandia controversy triggered an expansive U.S. Senate Finance 
Committee inquiry and bipartisan report highly critical of both GlaxoSmithKline (“GSK”) and 
the FDA.  See STAFF OF S. COMM. ON FINANCE, 111TH CONG., REP. ON GLAXOSMITHKLINE 
AND THE DIABETES DRUG AVANDIA 1 (Comm. Print. 2010) [hereinafter REPORT ON AVANDIA].  
This medication, introduced to the market in 1999 and prescribed to hundreds of thousands of 
patients annually to treat type 2 diabetes, caused 83,000 heart attacks between 1999 and 2007, 
according to the FDA’s own estimates.  Id. at 1–4; Gardiner Harris, Research Ties Diabetes Drug 
to Heart Woes, N.Y. TIMES, Feb. 20, 2010, at A1.  GSK researchers identified a link between 
Avandia and serious heart disease in 2004, 2005, and 2006, the FDA issued a warning in 2007, 
the FDA’s top officials in the Office of Surveillance and Epidemiology recommended a full 
market recall, and internal FDA reports indicated that switching Avandia patients to an alternative 
drug could prevent about 500 heart attacks and 300 cases of heart failure each month.  REPORT 
ON AVANDIA, supra, at 14, 93; Harris, supra.  According to the Senate Report, executives at the 
pharmaceutical company “attempted to intimidate independent physicians, focused on strategies 
to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought 
ways to downplay findings that a competing drug might reduce cardiovascular risk.”  REPORT ON 
AVANDIA, supra, at 1.  GSK responded by challenging the report and defending Avandia.  Id. at 
8.  Although GSK is undertaking another round of clinical trials to research the increased risk of 
heart disease, those are not projected to be completed until 2020.  Harris, supra.  Many 
lawmakers, consumer advocates, and other stakeholders are calling for regulatory reform of the 
FDA to grant officials in the Office of Surveillance and Epidemiology independent decision-
making power on par with that of officials who approve drugs.  Alyah Khan, Recent Avandia 
Report Sparks Concerns Over Internal FDA Power Struggle, FDA WK., Feb. 26, 2010, at 4, 4.  
This suggestion was made years earlier, including in the 2006 Institute of Medicine’s Report on 
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determined to actually cause fractures of the thigh bone and degeneration of 
the jawbone.161  In addition, a whole generation of teenagers with severe acne 
was treated with Accutane, on the market in 1982, which now is associated 
with inflammatory bowel disease, ulcerative colitis, Crohn’s disease, other 
gastrointestinal disorders, liver damage, birth defects, and suicidal thoughts.162  
Roche, the manufacturer, pulled Accutane from the market on June 29, 
2009.163  Many commercial drug developers and their supporters blame the 
FDA for the drop-off in new drug approvals, claiming the FDA has been too 
strict.164  Others attribute the fall to an industry that is clinging to the low 
science and regulatory standards of the past, stretching the commercial lives of 
pharmaceuticals through manipulation of the patent system, and contriving 
“me too” drugs rather than engaging in genuine innovation.165  When the 
Vioxx controversy substantiated doubts about the FDA’s reliability in 
regulating the biopharmaceutical market,166 the Agency responded by raising 
 
the FDA and in the law literature.  INST. OF MED., supra note 67, at 1, 3; see Thomas, supra note 
58, at 379. 
 161. Kolata, supra note 158. 
 162. Steven Bushong, Accutane Off Shelves, but Lawsuits Live, COLUMBUS DISPATCH, July 3, 
2009, at A1; Accutane Side Effects, DRUG WATCH, http://www.drugwatch.com/accutane/side-
effects.php (last modified Sept. 30, 2011). 
 163. Accutane Side Effects, supra note 162; Press Release, Roche Pharmaceuticals, Roche 
Discontinues and Plans to Delist Accutane in the U.S. (June 29, 2009), available at 
http://www.rocheusa.com/portal/synergy/static/file/synergy/alfproxy/download/1414-cd2ddc12 
b4d211deadd62f6357bc6b3c/last/roche%20discontinues%20and%20plans%20to%20delist%20ac
cutane%20in%20the%20u.s..pdf. 
 164. For a thoughtful argument of over-regulation, see RICHARD A. EPSTEIN, OVERDOSE: 
HOW EXCESSIVE GOVERNMENT REGULATION STIFLES PHARMACEUTICAL INNOVATION (2006).  
Note, however, that Professor Epstein does not directly address or challenge the core proposal of 
this Article—changing the core science standard in the context of the existing regulatory 
infrastructure. 
 165. See ANGELL, supra note 105, at 7–10, 13–17. 
The culture within the FDA, [is] one where the pharmaceutical industry, which the FDA 
is supposed to regulate, is seen by the FDA as its client instead.”  The lack of adequate 
regulation of the pharmaceutical industry by the FDA has led to many deaths and recalls 
of unsafe drugs, such as Vioxx, that the FDA had approved for public use [in 1999].  As 
Sen. Charles Grassley (R-Iowa) explained, “[c]onsumers should not have to second-guess 
the safety of what’s in their medicine cabinet.”  Unfortunately, many consumers suffer as 
a result of the current ineffective state of the FDA’s regulatory framework governing the 
drug testing and approval process. 
Aldes, supra note 54, at 463 (footnotes omitted). 
 166. For an excellent treatment of the Vioxx controversy with a focus on the overall U.S. and 
EU regulatory processes for pharmaceuticals, see Thomas, supra note 58.  Vioxx illustrates all 
too vividly that, without meaningful regulatory reform, it may take many years of market use; 
tremendous financial costs to consumers, taxpayers, and other payers; lost opportunities to 
improve human health; and even the loss of many human lives before serious product 
shortcomings are confronted.  In a 2002 broadcast journalism documentary entitled Bitter 
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its level of scrutiny, which has generated substantial drug sponsor demand for 
specialized toxicology studies by CROs.167  In fact, Vioxx and related concerns 
about FDA effectiveness inspired inquiry and generated corroborating reports 
on deficiencies from the Government Accountability Office (“GAO”), the 
Institutes of Medicine (“IOM”), and congressional hearings.168  These 
 
Medicine: Pills, Profit, and the Public Health, supra note 141, Vioxx was challenged on many 
levels—several years before its market recall.  Nevertheless, the product remained on the market 
at tremendous cost above over-the-counter alternatives such as Ibuprofen, only to be exposed and 
pulled from the market in 2004.  Thomas, supra note 58, at 366, 368. 
 167. Nagano, supra note 1.  CROs are commercial service providers that meet both basic and 
clinical research needs, and the business is burgeoning.  Id.  Unfortunately, guidance and 
enforceable law-policy to protect human subjects has not been introduced in sync with this trend: 
The globalization of medical research is, in effect, quickly outpacing the development of 
internationally accepted ethical guidelines for the conduct of research.  For many medical 
researchers working in resource-poor countries, ethical decision-making is like sailing in 
the days before modern navigation; one is never quite sure where one is, or in what 
direction one is headed. 
Daniel W. Fitzgerald & Angela Wasunna, Away from Exploitation and Towards Engagement: An 
Ethical Compass for Medical Researchers Working in Resource-Poor Countries, 33 J.L. MED. & 
ETHICS 559, 559 (2005); see also Malinowski, supra note 44, at 70–71 (offering several options 
for dealing with the gap); Jennifer L. Gold & David M. Studdert, Clinical Trials Registries: A 
Reform That Is Past Due, 33 J.L. MED. & ETHICS 811, 811 (2005) (supporting the establishment 
of a conclusive registry for clinical trials conducted abroad); Joe Stephens, Where Profits and 
Lives Hang in Balance, WASH. POST, Dec. 17, 2000, at A1 (discussing the lack of regulation and 
oversight characteristic of trials in some foreign countries). 
A sign of the trend: In August, Princeton, N.J.-based CovanceCVD, the largest U.S. CRO, 
struck a deal with Eli Lilly to buy Lilly’s R&D labs in Indiana for $50 million.  The deal 
will transfer 260 Lilly employees to Covance.  Lilly also guaranteed Covance a 10-year 
business contract worth $1.6 billion. 
Nagano, supra note 1. 
 168. Both the GAO and IOM have criticized the FDA’s performance regulating new drugs in 
the marketplace and emphasized the need to make the clinical research data submitted for market 
approval transparent to the public.  U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67, at 5; 
INST. OF MED., supra note 67, at 3.  Neither Congress nor the FDA have addressed the possibility 
that the drop-off in innovative new drug approvals and poor performance of many on the market 
are an indication that the integrity of the entire forthcoming generation of biopharmaceuticals has 
been jeopardized by law and policy that comprehensively integrated academia and industry 
without shoring up the public nature of science.  Michael J. Malinowski, Keynote Address: A 
Discourse on the Public Nature of Research in Contemporary Life Science: A Law-Policy 
Proposal to Promote the Public Nature of Science in an Era of Academia-Industry Integration, in 
BIENNIAL REVIEW OF LAW, SCIENCE & TECHNOLOGY 1, 9–12 (2010).  During the span of the 
career of a single academic researcher, norms have shifted from industry independence, 
collegiality, disclosure and sharing of materials and information, quick and unfettered 
publication, and broad dissemination of information that invited meaningful scrutiny and rigorous 
peer review to strong technology transfer administration within academic research institutions, no 
communication without executed confidentiality and disclosure agreements and provisional 
patent applications, no publication without sponsor preapproval, and no sharing of materials 
without executed material transfer agreements.  See id. at 9–19. 
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questions about the sufficiency of drug regulation and overall agency 
performance prompted FDA Commissioner Margaret Hamburg, when newly 
appointed, to establish a task force with the mission of developing 
recommendations to increase transparency of the Agency’s activities and 
decision-making.169 
Avandia illustrates a trend that accompanied modernization of the Agency 
through the FDAMA: conditional market access with reliance upon post-
marketing studies for safety and efficacy assurances.170  With the introduction 
of user fees under the PDUFA171 and modernization through FDAMA,172 the 
Agency has approved drugs based upon surrogate endpoints—indications that 
the drug performs, rather than definitive proof—and conditioned upon follow-
on clinical studies.173  Sixty-four drugs reached the market conditionally 
between 1992 and 2008.174  According to the GAO, the FDA has allowed 
drugs to stay on the market even when follow-up studies showed they did not 
save lives.175  Although more than one-third of these conditional studies are 
pending, the FDA never has pulled a drug from the market because of a failure 
to do required follow-up about actual benefits—even when the information is 
 
 169. Press Release, U.S. Food & Drug Admin., FDA Forms Transparency Task Force (June 
2, 2009), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 
163899.htm.  In 2004, Congress considered measures to force public disclosure of clinical data 
through the Internet to enable scrutiny by the medical and science communities, but then backed 
away when some of the major pharmaceutical companies announced they would do so 
voluntarily.  See Ted Agres, Congress Wants Data to Be Free, DRUG DISCOVERY & DEV., Nov. 
2004, at 14; Editorial, Hiding the Data on Drug Trials, N.Y. TIMES, June 1, 2005, at A20 
(commenting on a government survey that “determined that three of the largest drug companies 
[Merck, GlaxoSmithKline, and Pfizer] have effectively reneged on their pledges to list trials in a 
federal database”); Tamsin Waghorn, Rattled Drug Giants Act Over Safety Concerns, EXPRESS, 
Jan. 7, 2005, at 78. 
 170. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 
130, 111 Stat. 2296, 2231–32 (codified at 21 U.S.C. 356b; 21 U.S.C. § 355a (2006)).  The 
Agency’s mission was expanded from ensuring efficacy and safety to including efficiency.  See 
supra note 66 and accompanying text. 
 171. Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (codified 
primarily at 21 U.S.C. § 379g–h).  PDUFA, which was enacted with a five year sunset provision, 
has been reauthorized three times.  See supra note 66 (PDUFA II enacted in conjunction with 
FDAMA in 1997); Public Health Security and Bioterrorism Preparedness and Response Act of 
2002, Pub. L. No. 107-188, §§ 501–509, 116 Stat. 594, 687–694 (PDUFA III); Food and Drug 
Administration Amendments Act of 2007, Pub. L. No. 110-85, §§ 101–109, 121 Stat. 823, 825–
842 (codified as amended in scattered sections of 21 U.S.C.) (authorizing PDUFA IV through 
2012). 
 172. Food and Drug Administration Modernization Act of 1997, 111 Stat. 2296. 
 173. Evans, Seven Pillars, supra note 24, at 454 n.240, 478, 486. 
 174. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 74, at 15.  For a critique of the FDA’s 
post-market decision-making process, see U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67. 
 175. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 74, at 32–33. 
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more than a decade overdue.176  This failure is consistent with GAO and IOM 
declarations that the FDA’s performance post drug approval is substandard.177 
The very integrity of contemporary drug science has been called into 
question.  Arguably, “government interventions are necessary to protect and 
preserve the public nature of science, which is essential to shore up the 
contemporary science enterprise.”178  Aggressive integration of academia and 
industry has created a proliferation of conflicts of interest, and the public 
nature of science—collegiality, communication, transparency, and 
accountability—has shifted in the direction of secrecy.179  In the words of one 
observer, “It has turned universities into commercial entities, created a 
multibillion-dollar industry of technology transfer, and subsidized virtually 
every biotechnology company and discovery of the past twenty-five years.”180  
The science publications depended upon for scrutiny, accountability, and 
human health assessment have also embraced commercialization—evident by 
conflicts of interest controversies and the journals’ imposition of high cost 
barriers to access their publications:181 
 
 176. Id. at 33.  For example, Shire Laboratories failed to complete a study for ProAmatine, a 
medication for low blood pressure, for more than thirteen years.  Id. at 33–34. 
 177. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67, at 18–36; INST. OF MED., supra 
note 67, at 1. 
 178. Malinowski, supra note 168, at 23. 
 179. Id. at 13–19. 
 180. Lorelei Ritchie de Larena, The Price of Progress: Are Universities Adding to the Cost?, 
43 HOUS. L. REV. 1373, 1375 (2007).  For another evaluation of the Bayh-Dole Act, which gave 
universities greater patent rights, see DAVID C. MOWERY ET AL., IVORY TOWER AND INDUSTRIAL 
INNOVATION: UNIVERSITY-INDUSTRY TECHNOLOGY TRANSFER BEFORE AND AFTER THE BAYH-
DOLE ACT (2004). 
 181. Malinowski, supra note 168, at 16.  Several of the most renowned science publications, 
including the New England Journal of Medicine and Journal of the American Medical 
Association (“JAMA”), have been involved in embarrassing conflicts of interest controversies.  
See Linda A. Johnson, New England Journal of Medicine Admits Lapses in Ethics Policy, CHI. 
SUN-TIMES, Feb. 24, 2000, at 21 (reporting that the “New England Journal of Medicine admitted 
violating its financial conflict-of-interest policy 19 times over the last three years in its selection 
of doctors to review new drug treatments”). 
The primary guidance for conflict of interest management by medical journals is the 
Uniform Requirements for Manuscripts Submitted to Biomedical Journals, a consensus 
document issued and subsequently revised by the International Committee of Medical 
Journal Editors (ICMJE) and allegedly utilized by more than 500 journals.  See 
International Committee of Medical Journal Editors, Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, 277 JAMA 927, 927 (1997). . . . Despite 
widespread utilization of the ICMJE requirements, according to a report published in the 
April 2001 issue of Science and Engineering Ethics by Sheldon Krimsky and co-authors 
from the University of California at Los Angeles, “[i]n reviewing 61,134 scholarly articles 
published in 181 academic journals in 1997, researchers . . . found that just one-half of 1 
percent detailed personal financial interests, including consulting arrangements, 
honorariums, expert witness fees, company equity and stock, and patents.”  Sheryl Gay 
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The vast capacity to publish research and to share knowledge is tainted by 
conflicts of interest which threaten the reliability and integrity of the peer 
review process and, consequently, the underlying research.  Governments, 
professional societies, and most science journals have failed to introduce and 
enforce the mechanisms necessary to manage conflicts of interest in an era of 
aggressive commercialization with meaningful confidence. 
Also, industry has directly increased its influence over government and the 
general public substantially over the last few decades.182  PDUFA 
legislation,183 direct interface between industry and the broader government 
through extensive lobbying,184 and direct communication with the general 
public through billions of dollars invested in marketing annually have raised 
concerns and inspired calls for more regulation.185 
III.  LAW-POLICY ALCHEMY: A PROPOSAL TO CHANGE THE SCIENCE 
STANDARD IN HUMAN CLINICAL RESEARCH FROM GOLD TO PLATINUM 
The FDA science standard for drug approval and the law-policy 
implementing it are, at best, dangerously dated—to the detriment of drug 
development, the practice of medicine, and human health.186  Nevertheless, the 
commercial interests vested in new drug development, domestic and 
international, are too influential and too wedded to GD for an expansive break 
from the past to be a realistic possibility in the foreseeable future.187  Under 
PDUFA, which generates the salaries of more than 900 FDA reviewers 
through the collection of user fees, industry has tremendous ongoing 
negotiation leverage given the inclusion of five-year sunset provisions in each 
PDUFA renewal coupled with two decades of FDA financial dependence for a 
considerable portion of its new drug review operating budget.188 
Arguably, wholly uprooting the entrenched science standard, even if this 
were a viable option, would not be desirable given the approximately fifteen-
 
Stolberg, Scientists Often Mum About Ties To Industry, N. Y. TIMES, Apr. 25, 2001, at 
A17.  Moreover, those disclosures all appeared in just one-third of the 181 journals.  Id. 
Michael J. Malinowski, Institutional Conflicts and Responsibilities in an Age of Academic-
Industry Alliances, 8 WIDENER L. SYMP. J. 47, 59 n.57 (2001). 
 182. See Thomas, supra note 58, at 376. 
 183. The PDUFA legislation and user fee system are addressed supra notes 170–74 and 
accompanying text. 
 184. Commentators have estimated that there are as many as six lobbyists working in 
Washington, D.C. on behalf of the pharmaceutical sector for every member of Congress.  Sharyl 
Attkisson, Health Care Lobbyists’ Rise to Power, CBS NEWS (Oct. 29, 2009), http://www.cbs 
news.com/stories/2009/10/20/cbsnews_investigates/main5403220.shtml; see also 20/20: Sick in 
America: Whose Body is it Anyway? (ABC News television broadcast Sept. 14, 2007). 
 185. ANGELL, supra note 105, at 118–21; See Thomas, supra note 58, at 366. 
 186. See U.S. FOOD & DRUG ADMIN., supra note 141, at i. 
 187. See supra note 184 and accompanying text (noting the industry’s lobbying resources). 
 188. See supra note 171 for a discussion of PDUFA I–IV. 
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year timeline to develop each innovative new drug and the transitional nature 
of ongoing science in the drug development pipeline.189  Such a major change, 
especially if forced through law-policy that imposes more clinical trial 
obligations, could chill investment in pharmaceutical R&D, which is sorely 
needed during this time of historically high drug development costs, product 
disappointments, and economic challenges that extend well beyond the 
biopharmaceutical sectors.190 
Although drug development is evolving in the direction of precision 
through genomics (genetic expression),191 proteomics (protein expression),192 
and related fields, overall, the endeavor still remains too crude to adopt SSRD 
as a substitute for traditional GD.193  As observed by the FDA’s Janet 
Woodcock, an agency leader under several presidential administrations, both 
Democratic and Republican, “At this time, medical practice is predicated on 
observation.  For example, we still collectively categorize lung cancer as we 
did one hundred years ago.  We still are not sophisticated.  We don’t know 
what the actual molecular cause of that particular cancer is in that particular 
person because we don’t look for it.”194  However, the biopharmaceutical 
sectors certainly have the resources and capabilities to rise to the occasion of a 
higher standard in clinical research than traditional GD.195 
 
 189. See BIOTECHNOLOGY INDUS. ORG., supra note 132, at 38; BioBytes: The Biotech Drug 
Delivery Timeline, BIOTECHNOLOGY INDUS. ORG., http://www.bio.org/content/biobytes-biotech-
drug-delivery-timeline (last visited Dec. 29, 2011) (providing a short video discussing the drug 
development process); Drug Discovery Timeline, PHRMA, http://www.phrma.org/media/multi 
media/drug-discovery-timeline (last visited Dec. 29, 2011) (same). 
 190. Consider that when former President Clinton and former Prime Minister Tony Blair 
made a statement on March 14, 2000, that was critical of biotechnology patenting, the sector 
dropped by $100 billion over the next 24 hours.  Malinowski, supra note 13, at 60 n.167. 
 191. See supra notes 124–125, 134 and accompanying text. 
 192. See generally Genomics Revolution, supra note 13 (discussing the advantages of 
genomics, including protein expression). 
 193. Patient-Tailored Medicine Part One, supra note 13, at 35 (assessing that the advent of 
personalized medicine is at least a decade in the future); Patient-Tailored Medicine Part Two, 
supra note 13, at 42. 
 194. Woodcock, supra note 135, at 93.  Sophisticated genetic screening capabilities exist, but 
that is not the equivalent of them being commercially available.  See Malinowski, supra note 13, 
at 56–58.  For example, in April 2010 scientists announced a screening technique that can predict 
approximately three quarters of smokers who will develop lethal lung cancers.  Joseph Hall, 
Smokers’ Odds Just Got a Lot Better, TORONTO STAR, Apr. 8, 2010, at A1.  Science researchers 
also have developed a test that measures the expression of twenty-one genes to quantify the risk 
of breast cancer recurrence and make better treatment decisions.  BIOTECHNOLOGY INDUS. ORG., 
supra note 132, at 35.  The National Institutes of Health is advancing testing in oncology through 
The Cancer Genome Atlas, a project to map gene variations that cause cancer, spur its growth, 
and cause therapeutic resistance.  Id. 
 195. See BIOTECHNOLOGY INDUS. ORG., supra note 132, at 2.  See also supra note 141 and 
accompanying text.  Visit the official sites of the industry’s trade organizations: the 
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A meaningful, pragmatic transition is needed: SSRD should be introduced 
as a complement or nested research methodology to GD to shift more 
meaningful understanding of pharmaceuticals from clinical care (the delivery 
of health care to patients) to clinical research; to lessen experimentation on 
patients in the delivery of their care through physician off-label use, which is 
removed from regulations to protect human subjects;196 and to infuse 
responsiveness to the increasing precision enabled in both drug development 
and the delivery of care by contemporary genetic science.197  “For biomedical 
 
Biotechnology Industry Organization (“BIO”) at www.bio.org, and the Pharmaceutical Research 
and Manufacturers of America (“PhRMA”) at www.PhRMA.org. 
 196. See supra notes 115–20 and accompanying text (describing the rise in off-label 
prescribing).  Protections for human subjects are afforded under the Common Rule triggered by 
federal funding of research and FDA regulations imposed as a condition to engage in research 
under its watch—to which off-label use of drugs does not apply.  See 45 C.F.R. § 46.122 (2010); 
21 C.F.R. § 50.1 (2010). 
 197. Cf. John F. Niblack, Toward a Structured National Program to Speed the Invention and 
Development of New Technologies for Measuring the Progression of Chronic Diseases, in 
BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, at xviii–
xxi (Gregory J. Downing ed., 2000) (describing the role of genomic technology in preventing and 
treating chronic disease); Robert H. Glassman & Anthony Y. Sun, Biotechnology: Identifying 
Advances from the Hype, 3 NATURE REVIEWS: DRUG DISCOVERY 177 (2004) (considering the 
causes of slow developments in biotechnology and ways to increase biotechnology value 
capture); David F. Horrobin, Modern Biomedical Research: An Internally Self-Consistent 
Universe with Little Contact with Medical Reality?, 2 NATURE REVIEWS: DRUG DISCOVERY 151 
(2003) (calling for a critical assessment of the use of in vitro and animal models to understand 
human disease).  As observed by the FDA, 
Greater success along the critical path demands greater activity in a specific type of 
scientific research that is directed at modernizing the product development process.  Such 
research—highly pragmatic and targeted in its focus on issues such as standards, methods, 
clinical trial designs and biomarkers—is complementary to, and draws extensively from, 
advances in the underlying basic sciences and new technologies.  Without a concerted 
effort to improve the critical path, it is likely that many important opportunities will be 
missed and frustration with the slow pace and poor yield of traditional development 
pathways will continue to escalate. 
U.S. FOOD & DRUG ADMIN., supra note 141, at 29.  As stated by a proponent of applying SSRD 
in drug development research: 
Research in biomedicine appears to rely on randomized parallel group clinical trial 
designs and considers these trials the “gold standard” when determining treatment 
effectiveness.  However, large-scale trials contain inherent limitations in that they can be 
expensive and time consuming.  In addition, patients are unique and may not respond 
similarly to various treatments, and in those instances a randomized clinical trial design 
may be inappropriate.  Guidelines are established from the averaged study findings, which 
may not necessarily be applicable when evaluating suitable treatment options for 
individuals.  Specifically, patients treated in primary care settings may differ clinically 
from patients in the clinical trial, the patient diversity in the clinical trial may not 
generalize to certain patient populations, and the stringent trial criteria for accepting 
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researchers, the best course for increasing scientific understanding of relevant 
phenomena revolves around the utilization of a variety of methodological 
designs, with the research question of interest determining the choice of the 
design.”198  Although meaningful SSRD data could complicate GD trials and 
lengthen the drug approval process, understanding pharmaceuticals much more 
before they reach the market is sorely needed.199  Moreover, it is a cost that 
could be contained through incremental implementation and potentially offset 
through a reduction in the lost opportunities attributable to drug 
underdevelopment.  Although SSRD presumably would narrow the existing 
opportunity to oversell by making new drugs more thoroughly understood 
prior to their market entry, the extra data could raise the presently waning 
confidence of providers and patients—a “one-two punch” of science.  From a 
regulatory perspective, infusing more specificity into the product approval 
process, knowing much more about pharmaceuticals prior to putting them on 
the market, and, consequently, restricting the familiar level of off-label use are 
desirable and needed—and demanded increasingly by government policy 
makers and the general public.200 
The following discussion establishes the potential of SSRD to improve 
drug development and health care delivery, with emphasis on the practicality 
and feasibility of incorporating SSRD into human clinical research.  After 
identifying law-policy options, the Article emphasizes the use of positive 
commercial incentives based upon enacted legislation that has succeeded in 
getting desired human clinical trial research undertaken by industry—namely 
the BPCA and the ODA, each of which is addressed in the following 
discussion. 
A. SSRD’s Potential to Improve Drug Development and Delivery 
Wait-and-see dependence on the medical profession to sort out the impact 
of prescription medications on individuals, one patient at a time, in a trial-and-
error manner, “exposes patients to potentially harmful drug interactions and 
 
participants may not accurately reflect general patient populations.  This is an important 
consideration as the field of biomedicine strives to pursue cultural competency. 
JANOSKY ET AL., supra note 6, at 81–82 (footnotes omitted). 
 198. JANOSKY ET AL., supra note 6, at 25. 
 199. See supra Part II (addressing drug underdevelopment, including the limited number of 
drug targets used to treat all human ailments); infra Part III.C (describing the absence of 
regulatory oversight of drugs in light of the current dependence on the medical community on off-
label drug experimentation). 
 200. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 
Stat. 823 (codified as amended in scattered sections of 21 U.S.C.) (authorizing fees that will go 
toward expediting drug development and increasing post-market drug safety); U.S. FOOD & 
DRUG ADMIN., supra note 141, at 11. 
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delays potentially effective or the ‘right’ treatment.”201  As recognized by Dr. 
Janosky, an expert in SSRD, there is a strong parallel between SSRD and the 
actual delivery of health care: 
In a primary care setting, the patient generally exhibits symptoms and the 
physician follows evidence-based or appropriate steps to treat these symptoms.  
The physician evaluates the patient’s history, signs, symptoms, medical test 
results, and examines the patient, and subsequently implements a treatment or 
intervention if warranted. . . . In primary care settings, standardized procedures 
are employed that include objective measurement of the outcomes, such as 
systolic blood pressure measurements.  These design and intervention 
procedures are analogous to the standardized procedures used in single subject 
research designs, such as testing the effectiveness of a medication over a 
course of time.202 
SSRD, the very nature of which is close scrutiny of each of the individuals 
under study,203 could improve decision-making during the clinical trial process 
and actually increase flexibility in clinical research for drug development 
because it presents an opportunity to tailor interventions for specific subjects 
and to modify ineffective ones over the course of the period of study.204  A 
major practical advantage of SSRD over GD is that “[i]t overcomes some of 
the inherent limitations found in large-scale clinical trials, in that treatments 
are tailored for unique individuals and can also be modified over time.”205  
SSRD data could better enable sponsor decision-making for its GD 
counterpart, thereby saving them from investing hundreds of millions of 
dollars in the development and marketing of products like Vioxx, Avandia, and 
Accutane, each of which has exposed their manufacturers to substantial 
product liability and class action lawsuits.206  By addressing human variability 
through SSRD, drug sponsors could cut back significantly on the time and 
expense of human clinical trials that are required to put new drugs on the 
market, both of which have risen significantly in recent years.207  Moreover, 
there is an obvious ethics advantage in that many SSRD designs ensure that 
 
 201. Patient-Tailored Medicine Part One, supra note 13, at 28. 
 202. JANOSKY ET AL., supra note 6, at 81; see also Burke & Psaty, supra note 120, at 1684 
(noting the individualized nature of clinical health care); Patient-Tailored Medicine Part One, 
supra note 13, at 9 (same). 
 203. See supra Part I.B. 
 204. JANOSKY ET AL., supra note 6, at 81. 
 205. Id. at 82, 95 (“Single subject designs also provide greater flexibility for treatments, as 
ineffective interventions can be modified over the period of study.  Thus, single subject designs 
should be considered when conducting research in biomedicine, as the methodology and 
interventions can be tailored for specific individuals.” (footnotes omitted)). 
 206. For a thoughtful treatment of products liability in the context of pharmaceuticals, see 
Patient-Tailored Medicine Part Two, supra note 13, at 21–36. 
 207. See supra notes 78–84 and accompanying text. 
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each individual receives the treatment(s) and does not require denying patients 
access to potential treatments to create a control—a standard component of 
GD.208  SSRD could even enable research not practicable under GD.209  As 
explained by Professor Janosky, 
Specifically, at times it is difficult to find a large number of patients who have 
unique demographics or suffer from rare diseases.  Furthermore, large N 
studies can be time consuming.  One of the consequences of the time 
consuming nature of large N research is the difficulty in studying public health 
crises, for example.  Additionally, the exorbitant financial costs of large-
sample research often limit who is able to conduct such projects, at times 
risking an ethical dilemma with the linking of the researcher and the funder in 
mutual vested interests in the results.  For example, funding from 
pharmaceutical companies is often needed to conduct the multi-million dollar 
research necessary for evaluating the same drugs those companies produce.210 
SSRD, with its emphasis on responsiveness to human variability, offers an 
opportunity to identify genetic markers and to develop meaningful biomarker 
screens during the human clinical trial process.  Specifically, SSRD introduces 
an opportunity to use the clinical trial process to develop a bouquet of 
sophisticated genetic screens—for example, genetic tests that stratify patients 
in the trials to discern those most prone to responsiveness and those at higher 
risk for adverse events, and perfecting drug dosage on a person-by-person 
basis.211  Genetic differences impact responses to pharmaceuticals, and at times 
do so profoundly.212  Studies establish that enzyme variations in genes, with 
thirty or more enzymes typically coded for each gene, may have a profound 
impact on the rate that they are metabolized—a major consideration for what 
constitutes safe and effective dosing for individual patients.213  A noted 
illustration is the wide variation in patient reactions to asthma medications, 
 
 208. JANOSKY ET AL., supra note 6, at 27–28. 
 209. Id. at 28. 
 210. Id.  For further discussion of financial conflicts of interest in the research setting, see 
CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81. 
 211. While innovative new drug returns on the HGP have been disappointing thus far, 
genomics has introduced a new dimension of research opportunity and is impacting clinical 
medicine.  See Robert Goldberg & Peter Pitts, Prescription for Progress: The Critical Path to 
Drug Development 1, 7–9 (21st Century FDA Task Force Working Paper, 2006), available at 
http://www.manhattan-institute.org/pdf/CMP_FDA_Task_Force.pdf; Patient-Tailored Medicine 
Part One, supra note 13, at 8–9. 
 212. See Patient-Tailored Medicine Part One, supra note 13, at 7, 16–17. 
 213. PERSONALIZED MED. COAL., THE CASE FOR PERSONALIZED MEDICINE 4 (2006), 
available at http://www.cspo.org/outreach/md/docs/TheCaseforPersonalizedMedicine.pdf; 
Patient-Tailored Medicine Part One, supra note 13, at 16–17. 
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some of which studies have attributed to identified differences in genetic 
makeup.214 
B. The Feasibility of SSRD in Drug Development—Precedent and Practice 
Several trends suggest that drug sponsors should expect more scrutiny and 
demands for accountability from regulators, the medical community, and the 
general public: rising health care finance pressures, federal and state, domestic 
and international; increased transparency of market performance and market 
behavior through internet communication, including organized observation 
through patient and consumer protection groups; and pressure on the FDA to 
increase post-marketing regulation requirements and general enforcement.215  
SSRD could prove a means to meet and quell these pressures, and 
implementation is practicable: there is precedent for the use of SSRD in human 
clinical research to advance health care, albeit almost entirely outside of the 
context of biopharmaceutical development.216 
Extensive SSRD human clinical research has been done in applied 
behavior analysis and education,217 and “[n]umerous studies have highlighted 
the importance of the single subject design paradigm in primary care.”218  
Some especially notable disease-related group accomplishments utilizing 
SSRD include a large portion of the research studying treatments for aphasic 
patients (loss of the ability to articulate ideas or comprehend language due to 
brain damage from injury or disease), attention deficit hyperactivity disorder 
(“ADHD”), and diabetes.219  Many SSRD studies in the primary care setting 
have been premised upon raising the predictability of responsiveness to 
stimulant medications at various dosages, including an ambitious collective 
assessment study carried out in Australia more than two decades ago.  As 
summarized by Professor Janosky, 
[I]n the 1980s, McMaster University designed a service for community and 
academic physicians to facilitate the planning and conduction of single subject 
(N-of-1) trials.  The effectiveness of the trials was evaluated by the physicians’ 
management plans and confidence levels in the plans both prior to and 
following trials.  A total of 57 single subject trials were completed, with 50 
trials providing a definite clinical answer and 15 resulting in the physician 
 
 214. Lyle J. Palmer et al., Pharmacogenetics of Asthma, 165 AM. J. RESPIRATORY & 
CRITICAL CARE MED. 861, 861 (2002); Alix Weisfeld, Comment, How Much Intellectual 
Property Protection Do the Newest (and Coolest) Biotechnologies Get Internationally?, 6 CHI. J. 
INT’L L. 833, 835 (2006). 
 215. See supra notes 160, 168, and 200 and accompanying text. 
 216. Professor Janosky provides a full annotated bibliography of SSRD articles recently 
published in PsycInfo, MEDLINE, and PubMed.  JANOSKY ET AL., supra note 6, at 97–114. 
 217. See supra note 7 and accompanying text. 
 218. JANOSKY ET AL., supra note 6, at 83. 
 219. Id. at 82–84. 
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altering patient treatment.  In those 15 trials resulting in treatment adjustment, 
11 trials lead to physicians discontinuing the medication therapy they planned 
to administer indefinitely.  Trials that were not completed generally stemmed 
from patient’ or physician’ noncompliance or patient’ concurrent illness 
[sic].220 
Based upon these results reported by the collaborative team at McMaster 
University, single subject trials afford important opportunities for application 
in biomedicine, including directly improving patient clinical care.221 
SSRD experience in human clinical trials and in the primary care context over 
decades could be infused into drug development readily, creatively, and with 
flexibility, as demonstrated by Professor Gina Green: 
Unlike between-groups studies, single-case studies can be conducted in typical 
service settings like schools, treatment centers, hospitals clinics, and homes.  
Their focus on the development of individual behavior and their flexibility 
makes these methods especially well-suited for studying treatments for [autism 
spectrum disorders], given the large individual differences among people with 
those diagnoses. Single-case research methods also afford a means for 
practitioners as well as researchers to evaluate the effects of many types of 
treatments—behavioral, educational, medical, or combinations—with 
scientific rigor.222 
A report issued by the IOM in 2001, which provided initial guidelines for 
small clinical trials, is an affirmation of the feasibility and potential utility of 
SSRD in drug development.223  The report recognized the potential utility of 
these trials for a portfolio of situations, including rare diseases, unique study 
populations, individually tailored therapies, isolated environments (for 
example, health care in rural areas), emergency situations, and public health 
urgency.224 
An SSRD component to clinical trials for drug development would 
introduce several potential benefits, in addition to raising fundamental 
understanding about new drugs during the pre-market clinical research stage.  
The size and costs of GD trials have increased immensely in concert with the 
proliferation of the genetic sciences and associated precision—which by its 
very nature demands increased attention to human variability.225  The GD 
approach is demonstrating decision-making confusion and clinical trial 
 
 220. Id. at 82 (footnotes omitted). 
 221. Id. at 1. 
 222. Green, supra note 6, at 79. 
 223. INST. OF MED., SMALL CLINICAL TRIALS: ISSUES AND CHALLENGES 57–59 (Charles H. 
Evans, Jr. & Suzanne T. Ildstad eds., 2001). 
 224. Id. at 16 tbl.1-2; see also JANOSKY ET AL., supra note 6, at 2 (discussing the IOM Report 
and elaborating on SSRD methodology). 
 225. See supra notes 78–79 and accompanying text. 
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failures.226  As observed in an April 2010 report issued by the Institute of 
Medicine, approximately forty percent of all advanced clinical trials sponsored 
by the National Cancer Institute, organized under the GD gold standard for the 
most part, are never completed—resulting in a waste of money, effort, and lost 
opportunities to improve human health and reap financial returns.227 
An obvious primary question for implementation of SSRD is, given 
industry’s entrenched commitment to GD, how to use SSRD and GD together 
in drug development.  Johnston and Pennypacker, authors of a heavily-cited 
text on behavioral research that compares and contrasts SSRD and GD, 
propose that, where both are used, SSRD should be utilized to graph and check 
data for each subject as a quality control on GD reliance on inferential 
statistical techniques and interpretation to generate and explain data.228  In fact, 
they believe that all data should be subjected to SSRD scrutiny before it even 
is eligible for use in GD.229  Their primary concern is that group data risks 
obscuring individual patterns of responding: 
[T]he more an analytical procedure changes the investigator’s picture of the 
subject’s behavior as it actually happened, the greater the risk that the 
analytical procedure may exert more control over interpretations than do the 
data. . . . 
  A related guideline may be stated as follows: The more an investigator has 
to change the data to see something important, the greater the risk that the 
result is not that important or, perhaps, not even there.230 
To begin the transition into utilization of SSRD in biopharmaceutical 
R&D,231 one option is to pursue running SSRD and GD trials in parallel and 
throughout Phases I–III of the pre-market human clinical trial process.232  
Incorporating the Johnston and Pennypacker approach, SSRD trials could be 
started in advance and used to shape GD trials, and then as a quality control 
 
 226. Over the last five years, Phase III trials have expanded from 3000 to 20,000 subjects and 
their cost has doubled to reach $100 million.  See supra note 79 and accompanying text. 
 227. INST. OF MED., A NATIONAL CANCER CLINICAL TRIALS SYSTEM FOR THE 21ST 
CENTURY 29 (2010); Opinion, Faltering Cancer Trials, N.Y. TIMES, Apr. 25, 2010, at A11. 
 228. JOHNSTON & PENNYPACKER, STRATEGIES AND TACTICS, supra note 7, at 304.  Johnston 
and Pennypacker propose that researchers “not create group data until they have already 
conducted a thorough analysis of the individual data that is included.”  Id. 
 229. Id.  As explained by Johnston and Pennypacker, “One reason for this rule is that group 
data obscures individual patterns of responding.  Regardless of whether the collated data present 
an interesting or expected picture, they do not necessarily represent what can be seen by looking 
at the records from each individual subject.”  Id. 
 230. Id. at 298. 
 231. Imposing SSRD as a substitute for GD is not practicable or even desirable at this time.  
See supra notes 189–90 and accompanying text. 
 232. See supra Part I.A (discussing the phases of the clinical trial process). 
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throughout their duration.233  Another possible approach would be to use 
SSRD more intensely in a focused capacity—perhaps for specific trials, 
specific patient subpopulations, or for specific treatments, such as those for 
rare patient populations in conjunction with the Orphan Drug Act.234  
Specifically, “single subject designs may be nested within larger clinical trials 
to increase compliance and answer more detailed questions.  Single subject 
designs are particularly useful for answering questions regarding rare diseases, 
side effects, unique populations, emergency situations, and isolated 
environments, in which between-group designs would be unfeasible or 
impractical.”235 
Another option, and one that could be applied in conjunction with the 
others, would be to introduce SSRD services to assist physicians with market 
use of prescription drugs as an extension of Phase IV trials—an application 
strongly supported by the McMaster University study and ample primary care 
applications.236  In summary, 
Research supports the effectiveness of the single subject design, from studying 
treatments for rare patient populations to providing N-of-1 trial services in 
assisting physicians.  The single subject design is an innovative addition to the 
arsenal of available methodologies for primary care physicians, biomedical 
students, residents, medical research faculty, clinical practitioners, among 
others.  Consistent with the NIH Roadmap Initiative, increasing awareness of 
the utility in the single subject design could enhance treatment approach and 
evaluation both in biomedical research and primary care settings.237 
 
 233. See supra notes 228–30 and accompanying text. 
 234. See INST. OF MED., supra note 227, at 99 (describing a new strategy of using small 
“targeted trial designs”); JANOSKY ET AL., supra note 6, at 93–95 (describing the use of SSRD for 
a patient study involving a forty-two-year-old mixed race male with elevated blood pressure).  
“Treatments are often unavailable for unique patient populations or rare disorders, and 
researchers are left uncertain what designs or tools to use when implementing treatments.”  Id. at 
82. 
 235. JANOSKY ET AL., supra note 6, at 28–29 (footnotes omitted). 
 236. See id. at 82.  “This methodology is also particularly suited for primary care practice-
based research, where practitioners can tailor individualized treatments to improve outcomes.”  
Id. at 29. 
Tsapas and Matthews discussed that N-of-1 trials can be an optimal approach when 
treating chronic diseases such as diabetes mellitus, which frequently rely on clinical 
judgment and arbitrary criteria.  The authors stated that guidelines for treating diabetes 
have been criticized as being unreliable, as algorithms are generally established from 
“clinical judgment and experience.”  Single subject designs take into account the 
uniqueness of the individual, rather than using a standardized treatment that may not be 
effective for all diabetics. 
Id. at 83 (footnote omitted). 
 237. Id. at 95.  For documentation of the use of SSRD in biomedicine, see JANOSKY ET AL., 
supra note 6, at 97–114. 
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C. Law-Policy Catalysts to Turn Gold into Platinum 
Although “there is substantial proof that the current method of creating 
medicines for the general public is problematic and could prevent effective 
treatments from reaching the marketplace”,238 voluntary uptake of SSRD by 
drug developers is unlikely.  They are inclined to resist the official addition of 
SSRD into the regulatory process for the same reason they have been slow to 
introduce pharmacogenomics data (R&D based upon genetic expression239) in 
their applications in spite of FDA encouragement—fear that it will be used 
against them to limit their market reach.  The FDA has issued voluntary 
guidelines to promote submission of pharmacogenomics data which, in sync 
with SSRD, innately involves closer individual patient scrutiny—including at 
the genetic and molecular levels—and more extensive patient-centered data 
compilation during the clinical trial process.240  Unfortunately, the guidelines 
 
 238. Patient-Tailored Medicine Part One, supra note 13, at 5. 
 239. See supra Part II.B. 
 240. Press Release, U.S. Food & Drug Admin., FDA Works to Speed the Advent of New, 
More Effective Personalized Medicine (Mar. 22, 2005), available at http://www.fda.gov/News 
Events/Newsroom/PressAnnouncements/2005/ucm108423.htm.  As stated by the FDA, 
This guidance is intended to facilitate scientific progress in the field of 
pharmacogenomics and to facilitate the use of pharmacogenomic data in drug 
development.  The guidance provides recommendations to sponsors holding 
investigational new drug applications (INDs), new drug applications (NDAs), and 
biologics license applications (BLAs) on (1) when to submit pharmacogenomic data to the 
Agency during the drug or biological drug product development and review processes, (2) 
what format and content to provide for submissions, and (3) how and when the data will 
be used in regulatory decision making. 
U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: PHARMACOGENOMIC DATA 
SUBMISSIONS 1 (2005), available at http://www.fda.gov/downloads/RegulatoryInformation/Guid 
ances/UCM126957.pdf (footnote omitted) [hereinafter U.S. FOOD & DRUG ADMIN., GUIDANCE].  
For discussion of the clinical applications of pharmacogenomics and use of it to tailor therapies, 
see Pharmacogenomics and Its Role in Drug Safety, FDA DRUG SAFETY NEWSL. (U.S. Food & 
Drug Admin, Wash., D.C.), Winter 2008, at 24, available at http://www.fda.gov/downloads/ 
Drugs/DrugSafety/DrugSafetyNewsletter/ucm109169.pdf.  The FDA and the European 
Medicines Agency (“EMEA”) have promoted the voluntary submission of genomic data jointly.  
U.S. FOOD & DRUG ADMIN. & EUR. MEDS. AGENCY, GUIDING PRINCIPLES: PROCESSING JOINT 
FDA EMEA VOLUNTARY GENOMIC DATA SUBMISSIONS WITHIN THE FRAMEWORK OF THE 
CONFIDENTIALITY ARRANGEMENT (2006), available at http://www.fda.gov/downloads/Drugs/Sci 
enceResearch/ResearchAreas/Pharmacogenetics/ucm085378.pdf; Federico Goodsaid, U.S. Food 
& Drug Admin., Joint USFDA-EU Pharmacogenomic Initiatives (2006), available at 
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm119097.pdf (presentation 
on joint FDA-EU pharmacogenomic initiatives).  To implement the guidelines and develop 
related policy and standards, the FDA created the Interdisciplinary Pharmacogenomic Review 
Group (“IPRG”).  See CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG 
ADMIN., MANUAL OF POLICIES AND PROCEDURES 4180.2: MANAGEMENT OF THE 
INTERDISCIPLINARY PHARMACOGENOMICS REVIEW GROUP  (IPRG) (2005), available at 
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/StaffPoliciesandProcedures/ 
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have not overcome industry fear that genetic specification will break down 
disease groups and restrict market reach through narrower approvals, more 
defined product labels, reimbursement limitations, and less physician 
discretion to use these pharmaceuticals off label.  As explained by Dr. 
Woodcock, 
The primary policy problem right now is that most of these genetic tests are 
not being evaluated in clinical studies, and they are not being seen by the 
regulatory agencies.  Application in the official drug development regulatory 
process is stymied by concern about how these tests will be used by the 
marketing application reviewers.  This could present a real lost opportunity for 
any person who wants to take medicine in the foreseeable future.241 
Even when pharmacogenomics data make it onto drug labels,242 the underlying 
sponsor data released is limited, and the medical community often lacks the 
knowledge to make efficient use of it.243 
A thoughtful law-policy intervention beyond voluntary guidelines is 
essential to add a meaningful SSRD component to drug development.  Using 
the regulatory process to attempt to impose commercial uses on new drug 
candidates or specific types of human clinical trials on drug developers would 
invite allegations of undue impediment on the commercial freedom that is the 
touchstone of our private market system and introduce susceptibility to legal 
 
ucm073574.pdf (setting out the charter for and duties of the IPRG).  The FDA also has issued a 
decision tree for genomic data submission.  U.S. FOOD & DRUG ADMIN., GUIDANCE, supra, at 19. 
 241. Woodcock, supra note 135, at 93. 
 242. Although 121 new drug labels contain pharmacogenomic information with sixty-nine of 
them referring to human genomic biomarkers, more than sixty-two percent of those with human 
genomic information contain information related to drug metabolism and a large portion of the 
rest is associated with cancer treatments.  Felix W. Frueh et al., Pharmacogenomic Biomarker 
Information in Drug Labels Approved by the United States Food and Drug Administration: 
Prevalence of Related Drug Use, 28 PHARMACOTHERAPY 992, 994–95 (2008).  A noted example 
is the association between over expression of the genetic variance Her-2/neu and the breast cancer 
drug Herceptin.  See generally BAZELL, supra note 138 (describing this association in depth).  
Experience to date suggests that drug sponsors’ fear that pharmacogenomics data in the 
regulatory process will splinter their markets is not fully grounded given physician discretion and 
inclination to use drugs off label, including in combination with other drugs.  For example, 
though Herceptin was developed to treat a very specific form of aggressive breast cancer 
associated with over expression of the protein HER2, physicians have used it off label to treat 
others with some success.  In fact, in combination with Taxol, Herceptin has even been 
discovered to treat prostate cancer.  Herceptin and Taxol Combination Looks Promising for 
Prostate Cancer, PSA RISING MAG.(Nov. 3, 1999), http://www.psa-rising.com/medicalpike/her 
ceptintaxol.htm. 
 243. Kelly C. Lee et al., Pharmacogenomics: Bridging the Gap Between Science and 
Practice, 50 J. AM. PHARM. ASSOC. e1, e2 (2010). 
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challenges.244  The drug development regulatory regime embodies deference to 
commercial free speech, proprietary interests, profit incentives, and the 
discretion to practice medicine—as the FDA has been reminded by Congress 
and through several legal challenges during the genomics revolution.  For 
example, the House Report that accompanied FDAMA expressly states that 
“the FDA has no authority to regulate how physicians prescribe approved 
drugs in the context of their medical practice.  Physicians prescribing off-label 
uses of approved drugs is not within the jurisdiction of the FDA.”245  As for 
legal challenges, in 2000 the U.S. Court of Appeals for the District of 
Columbia dismissed a challenge to FDAMA provisions addressing 
manufacturer promotion of off-label use that claimed the provisions imposed 
an undue burden on commercial free speech in violation of the First 
Amendment.246  However, the Court based its decision on the fact that the 
parties reached agreement that there was no longer an issue after the FDA 
changed its stance.247 
Perhaps the most vivid recent illustration of the limits of agency authority 
to force studies on drug sponsors is the FDA’s attempt to fill the vacuum of 
pediatric studies for pharmaceuticals known to be prescribed to children.248  In 
 
 244. See, e.g., Ass’n of Am. Physicians and Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204, 
217–18 (D.D.C. 2002); infra notes 248–61 and accompanying text (challenging FDA rules 
proposing mandatory pediatric trials). 
 245. H.R. REP. NO. 105-310, at 60 (1997). 
 246. See Wash. Legal Found. v. Henney, 202 F.3d 331, 336–37 (D.C. Cir. 2000).  At issue in 
the case were “the FDA’s and Congress’ attempts to regulate two . . . promotional strategies: 
manufacturer dissemination to physicians of independent medical and scientific publications 
concerning the off-label uses of their products” (referred to as “enduring materials”), “and 
manufacturer support for Continuing Medical Education (CME) programs for doctors that focus 
on off-label uses.”  Id. at 332–33. 
 247. Id. at 336. 
 248. While it is a common practice for physicians to prescribe to children pharmaceuticals 
only approved for adult use, by doing so, they can expose children to various hazards.  Children 
may be given an ineffective dose or an overdose, and they face an increased risk of side effects.  
Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and 
Biological Products in Pediatric Patients, 62 Fed. Reg. 43,900, 43,901 (Aug. 15, 1997) (codified 
at 21 C.F.R. pts. 201, 312, 314, 601).  This happens because: 
Correct pediatric dosing cannot necessarily be extrapolated from adult dosing information 
using an equivalence based either on weight . . . or body surface area . . . . Potentially 
significant differences in pharmacokinetics may alter a drug’s effect in pediatric patients. 
The effects of growth and maturation of various organs, maturation of the immune 
system, alterations in metabolism throughout infancy and childhood, changes in body 
proportions, and other developmental changes may result in significant differences in the 
doses needed by pediatric patients and adults. 
Id.  Faced with insufficient information about a new medication, pediatricians often opt to 
prescribe their young patients older, less effective, but well-tested medication—as opposed to 
newer, more effective medication that has not been subjected to rigorous study on pediatric 
populations.  Id. at 43,900.  This practice keeps children from benefitting from state-of-the-art 
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fact, even today, pediatric data is insufficient, at times wholly lacking, for two-
thirds of prescription drugs.249  A 1994 study reported that six of the ten drugs 
most commonly prescribed to children had inadequate pediatric labeling,250 
which inspired the FDA to issue a rule and to introduce a voluntary, incentive-
based program to promote pediatric testing and labeling.251  The tone during 
this time, under David Kessler who was the FDA Commissioner from 1990 to 
1997, was administrative caution: 
I need to acknowledge the limits of FDA’s authority.  It is our job to review 
drug applications for the indications suggested by the manufacturer.  We do 
not have the authority to require manufacturers to seek approval for indications 
which they have not studied.  Thus, as a matter of law, if an application 
contains indications only for adults, we’re stuck.252 
To address this dearth of pediatric data even for drugs prescribed to 
children routinely, Congress codified a voluntary, incentive-based five-year 
program through a pediatric exclusivity provision in FDAMA.253  This 
program granted drug manufacturers six months of market exclusivity for their 
products—as opposed to just extending intellectual property rights—as an 
incentive for conducting pediatric studies.254  The FDA then went further and 
issued a “Pediatric Rule” in 1998 that mandated pediatric testing—both for 
drug candidates and those already approved for market use.255  The FDA was 
 
medication.  See Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of 
New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632, 66,632 (Dec. 2, 
1998) (codified at 21 C.F.R. pts. 201, 312, 314, 601).  Ironically, the status of children as a 
“protected group” under federal regulations to protect human subjects contributes to their 
exclusion as a study focus in clinical research.  See 45 C.F.R. §§ 46.401–.409 (2010) (setting out 
the restrictions on research involving children). 
 249. See supra note 21–22 and accompanying text; Carolina Martinez-Castaldi et al., Child 
Versus Adult Research: The Gap in High Quality Study Design, 122 PEDIATRICS 52, 52 (2008). 
 250. U.S. FOOD & DRUG ADMIN., THE PEDIATRIC EXCLUSIVITY PROVISION: JANUARY 2001 
STATUS REPORT TO CONGRESS, at iii (2001). 
 251. See Specific Requirements on Content and Format of Labeling for Human Prescription 
Drugs; Revision of “Pediatric Use” Subsection in the Labeling, 59 Fed. Reg. 64,240 (Dec. 13, 
1994) (codified at 21 C.F.R. pt. 201). 
 252. Ass’n of Am. Physicians and Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204, 218 (D.D.C. 
2002) (quoting David Kessler, FDA Comm’r, Address to the American Academy of Pediatrics 
(Oct. 14, 1992)). 
 253. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 111, 
111 Stat. 2296, 2305–09  (codified at 21 U.S.C. § 355a (2006)). 
 254. Id.; 21 U.S.C. § 355a(b)–(c) (2006). The FDA interpreted the provision broadly and 
provided the six-month extension to all drugs derived from the active moiety put under pediatric 
study.  U.S. FOOD & DRUG ADMIN., supra note 250, at 7. 
 255. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New 
Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632 (Dec. 2, 1998) (codified 
at 21 C.F.R. pts. 201, 312, 314, 601). 
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sued successfully under the Administrative Procedure Act256 with claims that 
promulgation of the Pediatric Rule was arbitrary and capricious and exceeded 
the FDA’s authority.257  The voluntary program worked but was only 
moderately successful.  As of April 2001, the FDA had issued a mere 188 
written requests covering 155 drugs already on the market and just thirty-three 
new drugs not yet approved.258  “As of April 1, 2001, only 28 drugs had been 
granted periods of exclusivity.”259  Most of these drugs did experience a 
labeling change of some degree to address pediatrics, but, according to an 
article published in 2001, only 37.5 percent constituted a significant change in 
safety or dosing.260  By discussions in 2001 to reauthorize the voluntary 
program, only twenty-five percent of drugs had been studied in children—just 
a five percent increase from the 1994 statistic.261 
While the litigation against the FDA rule was pending and the FDAMA 
voluntary program approached its January 1, 2002, sunset,262 Congress 
intervened with the Best Pharmaceuticals for Children Act.263  BPCA 
reinstated the FDAMA voluntary program for pediatric testing with the 
incentive of six months of market exclusivity and then went further by 
empowering the FDA to step over manufacturer resistance and get pediatric 
trials done by third parties through the National Institutes of Health or with 
funding from a federal trust.264  BPCA also provided a basis to strike the 
FDA’s Pediatric Rule.265  Regarding the BPCA’s effectiveness, critics have 
 
 256.  5 U.S.C. §§ 701–706 (2006). 
 257. Ass’n of Am. Physicians and Surgeons, 226 F. Supp. 2d at 222. 
 258. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-01-705T, PEDIATRIC DRUG RESEARCH: 
SUBSTANTIAL INCREASE IN STUDIES OF DRUGS FOR CHILDREN, BUT SOME CHALLENGES 
REMAIN 4 (2001).  By September 30, 2002, the FDA had issued a total of 256 written requests.  
Michelle Meadows, Drug Research and Children, FDA CONSUMER, Jan.–Feb. 2003, at 12, 15.  
For information about the Act, visit the official Internet site at Best Pharmaceuticals for Children 
Act, NAT’L INSTS. HEALTH, http://bpca.nichd.nih.gov/ (last modified Dec. 13, 2011). 
 259. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 258, at 2. 
 260. William Rodriquez et al., Adverse Drug Events in Children: The U.S. Food and Drug 
Administration Perspective, 62 CURRENT THERAPEUTIC RES. 711, 718 (2001). 
 261. S. REP. NO. 107-79, at 1–2 (2001). 
 262. 21 U.S.C. § 355a(j) (2000). 
 263. Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408 (2002) 
(codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.); see H.R. REP. NO. 107-
277, at 14 (2001) (explaining that while the incentive had been successful, it was not adequate to 
address the need for studies in certain drugs such as those with no patent protection or those for 
neonates); S. REP. NO. 107-79, at 2 (2001) (noting the success of the 1997 legislation as well as 
the need to augment its provisions). 
 264. See 42 U.S.C. § 284m(a), (b) (2006). 
 265. In the words of the court, “After examining: (1) specific provisions of the FDCA, as well 
as the Act’s broader context; (2) the legislative history of the BPCA; and (3) the conflict between 
the BPCA and Pediatric Rule, this court concludes that Congress has directly spoken to the issue 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
414 SAINT LOUIS UNIVERSITY LAW JOURNAL [Vol. 56:363 
pointed out that the BPCA approach shifted considerable drug development 
cost from manufacturers to taxpayers.266  Nevertheless, as of March 2004, 
pharmaceutical manufacturers had issued 346 requests to evaluate prescription 
drugs for pediatric use, ninety-seven drugs were granted six months of 
exclusivity, and new labels were approved for seventy.267  As of 2008, 145 
drugs had been issued exclusivity.268 
Another illustration of the success of Congress and the FDA to utilize 
positive commercial incentives to get desired clinical research undertaken in 
drug development is the Orphan Drug Act.  ODA is a rewards-based program 
that makes it commercially viable to develop drugs for small groups of patients 
through tax incentives, a seven-year period of market exclusivity, and other 
benefits.269  The targeted research is being done: some 350 orphan drugs have 
been approved in the U.S. market alone, and the program has been replicated 
by other countries.270  Orphan drug filings have increased, especially 
submissions from multinational pharmaceutical sponsors.  There is 
considerable overlap between the ODA methodology and suggestions from 
NIH and others to incorporate small clinical trials and SSRD into drug 
development with an initial focus on small, discernible patient groups. 
The effectiveness of commercial incentives to get desired clinical research 
done has been demonstrated through ODA and BPCA, as has the 
 
here and has precluded the FDA’s jurisdiction to promulgate the Pediatric Rule.”  Ass’n of Am. 
Physicians and Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204, 212 (D.D.C. 2002). 
 266. Lauren Hammer Breslow, Note, The Best Pharmaceuticals for Children Act of 2002: 
The Rise of the Voluntary Incentive Structure and Congressional Refusal to Require Pediatric 
Testing, 40 HARV. J. ON LEGIS. 133, 134 (2003).  For example, BPCA is costly: 
While the BPCA is a strong step forward for children’s health, it comes at a significant 
price.  The six-month patent extensions cost consumers hundreds of millions of dollars 
because of the delay in cheaper, generic drugs reaching the market.  In addition to the 
patent extensions, taxpayers will fund the drug studies that manufacturers refuse to 
conduct, which average about $3.87 million per drug. For fiscal year 2002, Congress 
appropriated $200 million to that end. 
Id. (citing PUB. CITIZEN CONGRESS WATCH, PATENTLY OFFENSIVE: CONGRESS SET TO EXTEND 
MONOPOLY PATENTS FOR CIPRO AND OTHER DRUGS 2 (2001), available at http://www.citizen. 
org/documents/ACF34F.pdf). 
 267. Leslie Kushner, Incentivizing Postmarketing Pharmaceutical Product Safety Testing 
with Extension of Exclusivity Periods, 19 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 519, 547–
48 (2009). 
 268. “As of Feb. 19, 2008, 145 drugs have been granted pediatric exclusivity.”  Id. at 548 
n.160. 
 269. Orphan Drug Act, Pub. L. No. 97-414, §§ 2, 4, 96 Stat. 2049, 2050–51, 2053–56 (1983) 
(codified as amended at 21 U.S.C. § 360cc; 26 U.S.C. 45C (2006)); Mark D. Shtilerman, 
Pharmaceutical Inventions: A Proposal for Risk-Sensitive Rewards, 46 IDEA 337, 342–43 
(2006). 
 270. Orphan Drug Designation (ODD) Information, CLINUVEL, http://www.clinuvel.com/ 
pharmaceutical-regulation/orphan-drugs (last visited Dec. 29, 2011). 
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ineffectiveness of soft incentives such as voluntary guidelines and the 
susceptibility of FDA mandates to legal challenge.  To implement SSRD into 
drug development as quickly, effectively, and pragmatically as possible, 
Congress and the FDA should build upon what has worked and an opportunity 
introduced by a new government initiative—introduction of a federal research 
center with the specific mission of helping industry overcome drug 
development difficulties.  Given the commonality between ODA—small, 
distinguishable disease groups—and SSRD, ODA should be modified to favor 
utilization of SSRD in program qualification and provide additional incentives 
for its use, including additional tax incentives, additional reviewer support and 
responsiveness, and an additional extension (at least one year, to make the total 
exclusivity eight years) of market exclusivity for approved products that 
complete SSRD studies.  The FDA would have the discretion, as it does with 
the base ODA program, to set criteria and determine eligibility—meaning the 
Agency could experiment with SSRD to assess its efficacy in varied 
applications. 
For drug development beyond the small disease groups that qualify for 
ODA status, Congress and the FDA should draw heavily from BPCA—
perhaps in a manner that, in addition to promoting SSRD overall, particularly 
favors use of SSRD in pediatric studies and studies of other distinguishable 
patient and disease groups to make up for the relative dearth of data over the 
years.  This approach would be closely consistent with the suggestions of 
SSRD experts in disciplines that have embraced the approach, including 
professors Green, Janosky, Johnston, and Pennypacker.271  SSRD studies 
should be solicited with the incentive of at least six months of additional 
market exclusivity for resulting products (pediatric studies with SSRD would 
be rewarded with a year or more of product exclusivity), and Congress should 
create a separate trust fund to enable the FDA to undertake these studies when 
industry sponsors refuse.  The fund should be established to direct the FDA to 
include post-marketing (Phase IV) studies with primary care physicians on 
both new and existing drugs to assist physicians with market use—along the 
lines of the McMaster University study and suggestions of Dr. Janosky.272  
Both the IOM and GAO have determined that the FDA does a grossly 
insufficient job once pharmaceuticals reach the market and recent experience 
with the disappointment of approved drugs confirms, suggesting that SSRD 
studies, consistent with the practice of medicine, could make a substantial 
contribution.273  An SSRD fund would impose a cost on taxpayers—a major 
 
 271. See supra Part III.B. 
 272. See supra note 220–22 and accompanying text. 
 273. See U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67, at 18; INST. OF MED., supra 
note 67, at 1. 
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criticism of BPCA.274  Nevertheless, the state of drug development, new drug 
disappointments, the potential of SSRD coupled with genetic precision to 
improve drug development and benefit health care, the need to lessen 
dependence on years of physician off-label use for meaningful understanding 
of new drugs, consumption of government regulatory resources for this 
disappointing return, and lost product opportunities for sectors that are a major 
presence in our economy suggest that taxpayer investment in such a fund 
would be more than justified—especially given the amount of funding taken 
from industry in user fees to cover FDA operations.  The federal government 
appears to have recognized as much through establishment of a billion dollar 
center to help industry create new drugs, headed by Dr. Francis Collins who 
led the U.S. government HGP effort and now is Director of NIH.275 
This center to assist drug development also should make SSRD a priority.  
Although the Center is focused primarily on basic research—for example, to 
use its state-of-the-art robotic screening capabilities to identify chemicals that 
influence enzymes—and animal studies, its mission also includes starting 
human trials.276  The center should broaden its clinical research vision and 
include SSRD.  The transition into clinical research in drug development 
involves a substantial increase of industry investment—money, research, and 
opportunity.  Contingent upon the outcome of research, investment correlates 
with industry commitment—meaning an inclination to want to work with the 
center to resurrect troubled drug development efforts that hold market 
potential.  The center, preferably working in conjunction with the FDA, could 
infuse SSRD to salvage developed drug R&D undertakings representing 
substantial time and research investments and financial investments of tens, if 
not hundreds, of millions of dollars.  The Center’s involvement in just Phase I 
trials could make significant contributions.277 
CONCLUSION 
The so-called gold standard for human clinical research in drug 
development, GD, no longer glitters—to the extent it ever really did.  The costs 
of relying too heavily on GD are self-evident, including a significant decline in 
new drug approvals in spite of historic investment and resources such as the 
map of the human genome, drug disappointments such as Vioxx and Avandia 
that have threatened the lives of the patients taking them and generated large 
 
 274. See supra note 265. 
 275. Harris, supra note 2. 
 276. Id. 
 277. See Aldes, supra note 54, at 464 (“Part of this oversight involves accounting for changes 
in medicine and trial design both of which affect drug testing.  As such, the FDA must 
acknowledge when changes occur, and subsequently modify protocols and regulations that 
govern the affected clinical trials.” (footnote omitted)). 
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class action law suits, and dwindling faith in the FDA as evident in the passage 
of the FDAAA in 2007 as well as the GAO and IOM reports issued in 2006.278 
The crude science past in drug development, which may have justified 
reliance on GD, no longer should control the genetics present and future of 
human clinical research in biopharmaceutical R&D and FDA market approval.  
Genetics is increasingly dominating the drug development pipeline, and the 
very nature of genomics is unprecedented scientific precision—working at the 
cellular, genetic, and molecular levels in living organisms to identify genetic 
expression, to reveal the origins and progression of disease, and to make 
connections between the two and develop drugs based upon those 
connections.279  Regulatory reform is needed to make the science standard for 
human clinical trials responsive to the significance of human individuality and 
variability—factors recognized innately in both genomics and the patient-
centered practice of medicine. 
This Article has proposed law-policy reforms to infuse an alternative 
science methodology into human clinical research for drug development—
SSRD.  SSRD shares the responsiveness of genetics-based R&D to the reality 
of individual human variability, and an SSRD complement to GD could prove 
a means to move drug development through its present state of puberty 
between the crude science past and genetics-based future.280  “The single 
subject design has been successful in illuminating research findings across a 
variety of disciplines.  It overcomes some of the inherent limitations found in 
large-scale clinical trials, in that treatments are tailored for unique individuals 
and can also be modified over time.”281 
The proposals to promote SSRD put forth in this Article are based upon 
commercial incentives and programs that have endured the threat of legal 
challenges—the ODA and the BPCA.282  The FDA has successfully used ODA 
and BPCA to get needed clinical research done on small disease groups and 
children that industry had avoided.  This Article also proposes to infuse SSRD 
into human clinical research through a billion-dollar government center 
recently established to help industry create new drugs.283  The objective, as 
expressed by NIH Director Francis Collins who will direct the center and 
headed the U.S. government’s effort to map the human genome, is to convert 
contemporary genetic science accomplishments into clinical applications that 
 
 278. Food and Drug Administration Amendmendts Act of 2007, Pub. L. No. 110-85, 121 Stat. 
823 (codified as amended in scattered sections of 21 U.S.C.); see supra notes 23–25, 67 and 
accompanying text; supra Part II. 
 279. See supra Part II.B. 
 280. See supra Parts III.A–B. 
 281. JANOSKY ET AL., supra note 6, at 95. 
 282. See supra notes 35–36 and accompanying text. 
 283. See Harris, supra note 2. 
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improve human health and move industry out of its fifteen year slump in new 
drug approvals.284 
The biopharmaceutical sectors have the resources and capabilities to meet 
a higher science standard in clinical research than GD—a standard that has 
resulted in ongoing drug underdevelopment.285  SSRD is an opportunity to 
introduce a gold standard that actually glitters in an age of genomics and shifts 
drug development in the direction of needed improvements to human health. 
 
 284. Id. 
 285. See supra Part II. 
